US20120094975A1

US20120094975A1 - Pyrido [5, 4-d] pyrimidines as cell proliferation inhibitors

Info

Publication number: US20120094975A1
Application number: US13/062,058
Authority: US
Inventors: Andreas Mantoulidis; Georg Dahmann; Peter Ettmayer; Christian Klein; Steffen Steurer; Irene Waizenegger; Stephan Karl Zahn
Original assignee: Boehringer Ingelheim International GmbH
Current assignee: Boehringer Ingelheim International GmbH
Priority date: 2008-09-08
Filing date: 2009-09-08
Publication date: 2012-04-19
Also published as: RU2011113402A; MX2011002431A; JP2012502010A; ZA201101090B; US8653087B2; WO2010026262A1; EP2350083B1; CA2736306A1; CN102203098A; IL211136A0; AR073501A1; NZ591493A; TW201014860A; KR20110063528A; CL2011000489A1; JP5576379B2; AU2009289196A1; EP2350083A1

Abstract

The present invention encompasses compounds of general formula (1) wherein the groups R¹to R⁴, X¹, X¹, X³, L¹and L²are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or anomalous cell pro-liferation, and the use thereof in such a treatment.

Description

The present invention relates to new compounds of general formula (1)
wherein the groups R¹to R⁴, X¹, X², X³, L¹and L²have the meanings given in the claims and specification and the tautomers, racemates, enantiomers, diastereomers and mixtures thereof and the salts of all these forms and their use as medicaments.

BACKGROUND TO THE INVENTION

Pyrimido[5,4-d]pyrimidines for inhibiting tyrosinekinases, which are involved in signal transduction, are described in WO 96/07657, WO 97/32880 and WO 97/32882.
The aim of the present invention is to discover new active substances which can be used for the prevention and/or treatment of diseases characterised by excessive or abnormal cell proliferation.

DETAILED DESCRIPTION OF THE INVENTION

It has now been found that, surprisingly, compounds of general formula (1), wherein the groups R¹to R⁴, X¹, X², X³, L¹and L²have the meanings given hereinafter act as inhibitors of specific signal enzymes which are involved in controlling cell proliferation. Thus, the compounds according to the invention may be used for example for the treatment of diseases connected with the activity of these signal enzymes and characterised by excessive or abnormal cell proliferation.
The present invention therefore relates to compounds of general formula (1)
wherein
R¹denotes hydrogen or a group optionally substituted by one or more identical or different R^band/or R^c, selected from among C_1-6alkyl, C_1-6haloalkyl, C_3-10cycloalkyl, C_6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl,
or
a suitable substituent, selected from among —OR^c, —SR^c, —NR^cR^c, —NR^cNR^cR^cand —S(O)R^c;
R²denotes a group optionally substituted by one or more identical or different R^band/or R^c, selected from among C_1-6alkyl, C_1-6haloalkyl, C_3-10cycloalkyl, C_6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl;
R³is selected from among hydrogen, C_1-4alkyl, halogen, —OH, —O(C_1-4alkyl), —NH₂, —NH(C_1-4alkyl) and —N(C_1-4alkyl)₂;
R⁴is selected from among hydrogen, —CN, —NO₂, —NH₂, —NH(C_1-4alkyl), —N(C_1-4alkyl)₂, C_1-4alkyl, C_1-4haloalkyl, C_1-4alkoxy, C_1-5cycloalkyl and halogen;
X¹, X²and X³are each selected independently of one another from among nitrogen and CR^4*,

- wherein at most two of the atoms X¹, X²and X³may be nitrogen atoms and R^4*are each selected independently of one another from among hydrogen, —CN, —NO₂, —NH₂, —NH(C_1-4alkyl), —N(C_1-4alkyl)₂, C_1-4alkyl, C_1-4haloalkyl, C_1-4alkoxy, C_1-5cycloalkyl and halogen;
  L¹is selected from among —CH₂—, —NH—, —NMe-, —O— and —S—;
  L²is selected from among —C(O)NH—, —C(O)N(C_1-4alkyl)-, —NHC(O)—, —N(C_1-4alkyl)C(O)—, —CH₂—NHC(O)—, —C(O)—, —C(S)NH—, —NHC(S)—, —NHCH₂—, —CH₂NH—, —S(O)₂NH—, —NHS(O)₂, —NHC(O)NH—, —OC(O)NH— and —NHC(O)O—;
  each R^bis a suitable substituent and is selected independently of one another from among —OR^c, —SR^c, —NR^cR^c, —ONR^cR^c, —N(OR^c)R^c, —NR^gNR^cR^c, halogen, —CN, —NO₂, —N₃, —C(O)R^c, —C(O)OR^c, —C(O)NR^cR^c, —C(O)NR^gNR^cR^c, —C(O)NR^gOR^c, —C(NR^g)R^c, —N═CR^cR^c, —C(NR^g)OR^c, —C(NR^g)NR^cR^c, —C(NR^g)NR^gNR^cR^c, —C(NOR^g)R^c, —C(NOR^g)NR^cR^c, —C(NNR^gR^g)R^c, —OS(O)R^c, —OS(O)OR^c, —OS(O)NR^cR^c, —OS(O)₂R^c, —OS(O)₂OR^c, —OS(O)₂NR^cR^c, —OC(O)R^c, —OC(O)OR^c, —OC(O)NR^cR^c, —OC(NR^g)R^c, —OC(NR^g)NR^cR^c, —ONR^gC(O)R^c, —S(O)R^c, —S(O)OR^c, —S(O)NR^cR^c, —S(O)₂R^c, —S(O)₂OR^c, —S(O)₂NR^cR^c, —NR^gC(O)R^c, —NR^gC(O)OR^c, —NR^gC(O)NR^cR^c, —NR^gC(O)NR^gNR^cR^c, —NR^gC(NR^g)R^c, —N═CR^cNR^cR^c, —NR^gC(NR^g)OR^c, —NR^gC(NR^g)NR^cR^c, —NR^gC(NOR^g)R^c, —NR^gS(O)R^c, —NR^gS(O)OR^c, —NR^gS(O)₂R^c, —NR^gS(O)₂OR^c, —NR^gS(O)₂NR^cR^c, —NR^gNR^gC(O)R^c, —NR^gNR^gC(O)NR^cR^c, —NR^gNR^gC(NR^g)R^cand —N(OR^g)C(O)R^cand the bivalent substituents ═O, ═S, ═NR^g, ═NOR^g, ═NNR^gR^gand ═NNR^gC(O)NR^gR^g, while these bivalent substituents may only be substituents in non-aromatic ring systems;
  each R^cindependently of one another denotes hydrogen or a group optionally substituted by one or more identical or different R^dand/or R^e, selected from among C_1-6alkyl, 2-6 membered heteroalkyl, C_1-6halo alkyl, C_3-10cycloalkyl, C_6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl;
  each R^dis a suitable substituent and is selected independently of one another from among —OR^e, —SR^e, —NR^eR^e, —ONR^eR^e, —N(OR^e)R^e, —N(R^g)NR^eR^e, halogen, —CN, —NO, —NO₂, —N₃, —C(O)R^e, —C(O)OR^e, —C(O)NR^eR^e, —C(O)NR^gNR^eR^e, —C(O)NR^gOR^e, —C(NR^g)R^e, —N═CR^eR^e, —C(NR^g)OR^e, —C(NR^g)NR^eR^e, —C(NR^g)NR^gNR^eR^e, —C(NOR^g)R^e, —C(NOR^g)NR^eR^e, —C(NNR^gR^g)R^e, —OS(O)R^e, —OS(O)OR^e, —OS(O)NR^eR^e, —OS(O)₂R^e, —OS(O)₂OR^e, —OS(O)₂NR^eR^e, —OC(O)R^e, —OC(O)OR^e, —OC(O)NR^eR^e, —OC(NR^g)R^e, —OC(NR^g)NR^eR^e, —ONR^gC(O)R^e, —S(O)R^e, —S(O)OR^e, —S(O)NR^eR^e, —S(O)₂R^e, —S(O)₂OR^e, —S(O)₂NR^eR^e, —NR^gC(O)R^e, —NR^gC(O)OR^e, —NR^gC(O)NR^eR^e, —NR^gC(O)NR^gNR^eR^e, —NR^gC(NR^g)R^e, —N═CR^eNR^eR^e, —NR^gC(NR^g)OR^e, —NR^gC(NR^g)NR^eR^e, —NR^gC(NR^g)SR^e, —NR^gC(NOR^g)R^e, —NR^gS(O)R^e, —NR^gS(O)OR^e, —NR^gS(O)₂R^e, —NR^gS(O)₂OR^e, NR^gS(O)₂NR^eR^e, —NR^gNR^gC(O)R^e, —NR^gNR^gC(O)NR^eR^e, —NR^gNR^gC(NR^g)R^eand —N(OR^g)C(O)R^eand the bivalent substituents ═O, ═S, ═NR^g, ═NOR^g, ═NNR^gR^gand ═NNR^gC(O)NR^gR^g, while these bivalent substituents may only be substituents in non-aromatic ring systems;
  each R^eindependently of one another denotes hydrogen or a group optionally substituted by one or more identical or different R^fand/or R^g, selected from among C_1-6alkyl, 2-6 membered heteroalkyl, C_1-6halo alkyl, C_3-10cycloalkyl, C_6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl;
  each R^fis a suitable substituent and is selected independently of one another from among —OR^g, —SR^g, —NR^gR^g, —ONR^gR^g, —N(OR^g)R^g, —N(R^h)NR^gR^g, halogen, —CN, —NO₂, —N₃, —C(O)R^g, —C(O)OR^g, —C(O)NR^gR^g, —C(O)NR^hNR^gR^g, —C(O)NR^hOR^g, —C(NR^h)R^g, —N═CR^gR^g, —C(NR^h)OR^g, —C(NR^h)NR^gR^g, —C(NR^h)NR^hNR^gR^g, —C(NOR^h)R^g, —C(NOR^h)NR^gR^g, —C(NNR^hR^h)R^g, —OS(O)R^g, —OS(O)OR^g, —OS(O)NR^gR^g, —OS(O)₂R^g, —OS(O)₂OR^g, —OS(O)₂NR^gR^g, —OC(O)R^g, —OC(O)OR^g, —OC(O)NR^gR^g, —OC(NR^h)R^g, —OC(NR^h)NR^gR^g, —ONR^hC(O)R^g, —S(O)R^g, —S(O)OR^g, —S(O)NR^gR^g, —S(O)₂R^g, —S(O)₂OR^g, —S(O)₂NR^gR^g, —NR^hC(O)R^g, —NR^hC(O)OR^g, —NR^hC(O)NR^gR^g, —NR^hC(O)NR^hNR^gR^g, —NR^hC(NR^h)R^g, —N═CR^gNR^gR^g, —NR^hC(NR^h)OR^g, —NR^hC(NR^h)NR^gR^g, —NR^hC(NOR^h)R^g, —NR^hS(O)R^g, —NR^hS(O)OR^g, —NR^hS(O)₂R^g, —NR^hS(O)₂OR^g, —NR^hS(O)₂NR^gR^g, —NR^hNR^hC(O)R^g, —NR^hNR^hC(O)NR^gR^g, —NR^hNR^hC(NR^h)R^gand —N(OR^h)C(O)R^gand the bivalent substituents ═O, ═S, ═NR^h, ═NOR^h, ═NNR^hR^hand ═NNR^hC(O)NR^hR^h, while these bivalent substituents may only be substituents in non-aromatic ring systems;
  each R^gindependently of one another denotes hydrogen or a group optionally substituted by one or more identical or different R^h, selected from among C_1-6alkyl, 2-6 membered heteroalkyl, C_1-6haloalkyl, C_3-10cycloalkyl, C_6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl;
  each R^his selected independently of one another from among hydrogen, C_1-6alkyl, 2-6 membered heteroalkyl, C_1-6haloalkyl, C_3-10cycloalkyl, C_6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl;
  while the compounds (1) may optionally also be present in the form of their tautomers, racemates, enantiomers, diastereomers and mixtures thereof, or also as pharmacologically acceptable salts of all the above-mentioned forms.

In one aspect (A1) the invention relates to compounds (1), wherein
R³denotes hydrogen.
In another aspect (A2) the invention relates to compounds (1), wherein
R³denotes —NH₂or —NHMe.
In another aspect (B1) the invention relates to compounds (1), wherein
R¹denotes hydrogen.
In another aspect (A1B1) the invention relates to compounds (1), wherein R¹and R³denote hydrogen.
In another aspect (B2) the invention relates to compounds (1), wherein
R¹is a group optionally substituted by one or more identical or different R^band/or R¹, selected from among 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl, and R^band R^care as hereinbefore defined.
In another aspect (B3) the invention relates to compounds (1), wherein
R¹is a 3-7 membered, monocyclic and nitrogen-containing heterocycloalkyl or 6-10 membered, bicyclic and nitrogen-containing heterocycloalkyl optionally substituted by one or more identical or different R^band/or R^c,
R¹is bound to the pyrimido[5,4-d]pyrimidine structure through a nitrogen atom, and R^band R^care as hereinbefore defined.
In another aspect (B4) the invention relates to compounds (1), wherein
R¹is a group optionally substituted by one or more identical or different R^band/or R^c, selected from among piperidyl, perhydro-1,4-diazepinyl, piperazinyl, octahydro-pyrrolo[1,2-c]pyrazinyl, 2,5-diazabicyclo[2,2,1]heptyl, octahydro-pyrido[1,2-c]pyrazinyl, perhydro-1,4-oxazepinyl, morpholinyl, pyrrolidinyl, perhydroazepinyl, thiomorpholinyl, thiazolidinyl and azetidinyl,
R¹is bound to the pyrimido[5,4-d]pyrimidine structure via a nitrogen atom, and R^band R^care as hereinbefore defined.
In another aspect (B5) the invention relates to compounds (1), wherein
R¹is a 2-methyl-2,7-diazaspiro[4.4]nonyl optionally substituted by one or more identical or different R^band/or R^c, which binds to the pyrimido[5,4-d]pyrimidine structure via a nitrogen atom,
and R^band R^care as hereinbefore defined.
In another aspect (B6) the invention relates to compounds (1) with one of the structural aspects B2 to B5,
wherein R¹is heterocycloalkyl which is bound to the pyrimido[5,4-d]pyrimidine structure via a nitrogen atom and is optionally substituted by one or more substituents, each independently selected from among R^b1and R^c1;

- each R^b1is selected independently of one another from among —OR^c1, —NR^c1R^c1, halogen, —C(O)R^c1and ═O, while the latter substituent may only be a substituent in non-aromatic ring systems,
- each R^c1independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different R^d1and/or R^e1, selected from among C_1-6alkyl, phenyl, C_3-10cycloalkyl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl,
- each R^d1is selected independently of one another from among —OR^e1and —NR^e1R^e1,
- each R^e1independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different C_1-6alkyl, selected from among
- C_1-6alkyl, C_3-10cycloalkyl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl.

In another aspect (B7) the invention relates to compounds (1), wherein
R¹is selected from among
In another aspect (B8) the invention relates to compounds (1), wherein
R¹denotes —NR^c2R^c3and
R^c2and R^c3are each defined as R^cdefined hereinbefore.
In another aspect (B9) the invention relates to compounds (1), wherein
R¹denotes —NR^c2R^c3and
R^c2is selected from among hydrogen, C_1-6alkyl, C_3-6cycloalkyl, phenyl, 5-6 membered heteroaryl and 3-7 membered heterocycloalkyl,
R^c3is a group optionally substituted by one or more identical or different R^d3and/or R^e3, selected from among C_1-6alkyl, C_1-6haloalkyl, C_3-10cycloalkyl and 3-14 membered heterocycloalkyl,
each R^d3is selected independently of one another from among halogen, —NR^e3R^e3and —OR^e3,
each R^e3independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different R^f3and/or R^g3, selected from among C_1-6alkyl, C_6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl,
each R^f3denotes —OR^g3and
each R^g3are each selected independently of one another from among hydrogen and C_1-6alkyl.
In another aspect (B10) the invention relates to compounds (1) with one of the structural aspects B8 or B9, wherein
R^c2denotes hydrogen.
In another aspect (B11) the invention relates to compounds (1), wherein
R¹is selected from among
In another aspect (B12) the invention relates to compounds (1) with one of the structural aspects B8 or B9, wherein
R^c2denotes methyl or ethyl.
In another aspect (B13) the invention relates to compounds (1), wherein
R¹is selected from among
In another aspect (C1) the invention relates to compounds (1), wherein
R⁴denotes fluorine, bromine, chlorine or methyl.
In another aspect (D1) the invention relates to compounds (1), wherein
X¹denotes CR^4*-1, X²denotes CR^4*-2and X³denotes CR^4*-3and

- R^4*-1, R^4*-2and R^4*-3are each selected from among hydrogen, fluorine, chlorine and methyl and at least two of the groups R^4*-1, R^4*-2and R^4*-3denote hydrogen.

In another aspect (D2) the invention relates to compounds (1), wherein
X¹, X²and X³each denote CH.
In another aspect (D3) the invention relates to compounds (1), wherein
X¹denotes nitrogen, X²denotes CR^4*-2and X³denotes CR^4*-3and R^4*-2and R^4*-3are each selected from among hydrogen, fluorine, bromine, chlorine and methyl and at least one of the groups R^4*-2and R^4*-3denotes hydrogen.
In another aspect (D4) the invention relates to compounds (1), wherein
X¹denotes nitrogen, X²denotes CH and X³denotes CH.
In another aspect (E1) the invention relates to compounds (1), wherein
L¹denotes —NH— or —NMe-.
In another aspect (F1) the invention relates to compounds (1), wherein
R²is a group optionally substituted by one or more identical or different R^band/or R^c, selected from among C_6-10aryl and 5-12 membered heteroaryl,
and R^band R^care as hereinbefore defined.
In another aspect (F2) the invention relates to compounds (1), wherein
R²is a group optionally substituted by one or more identical or different R^band/or R^c, selected from among phenyl and 5-6 membered heteroaryl, and R^band R^care as hereinbefore defined.
In another aspect (F3) the invention relates to compounds (1), wherein
R²is a 5-6 membered heteroaryl optionally substituted by one or more identical or different R^band/or R^c
and R^band R^care as hereinbefore defined.
In another aspect (F4) the invention relates to compounds (1),
wherein R²is a heteroaryl which is selected from among furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, triazolyl, isoxazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl and pyrimidyl, and is optionally substituted by one or two substituents, each independently selected from among C_3-7cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, 1-methylpropyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, 1-methylbutyl, 1-ethylpropyl, isopentyl, neopentyl, trifluoromethyl, difluoromethyl, fluoromethyl, tert.-butoxy, trifluoromethoxy,
In another aspect (F5) the invention relates to compounds (1), wherein
R²is a phenyl optionally substituted by one or more identical or different R^band/or R^c, and R^band R^care as hereinbefore defined.
In another aspect (F6) the invention relates to compounds (1), wherein
R²denotes a phenyl

- R⁵is selected from among hydrogen, C_1-6alkyl, —OC_1-6alkyl, C_1-6haloalkyl, —OC_1-6haloalkyl, C_3-7cycloalkyl and 3-7 membered heterocycloalkyl, all the above-mentioned groups optionally being substituted by C_1-6alkyl, —CN or —OH;
- R⁶is selected from among hydrogen, C_1-6alkyl, —OC_1-6alkyl, C_1-6haloalkyl, —OC_1-6haloalkyl, —CN, —OH, halogen, —NHC_1-6alkyl and —N(C_1-6alkyl)₂, the latter two optionally being substituted in the alkyl moiety by a substituent —N(C_1-6alkyl)₂;
- R⁷is selected from among hydrogen, —OC_1-6alkyl, halogen, —NHS(O)₂C_1-6alkyl, —S(O)₂NH₂, —S(O)₂NHC_1-6alkyl, —S(O)₂N(C_1-6alkyl)₂,

- - R⁹is selected from among hydrogen and C_1-6alkyl;
  - R^c4is hydrogen or a group optionally substituted by one or more identical or different R^d4and/or R^e4, selected from among C_1-6alkyl and 3-14 membered heterocycloalkyl;
  - each R^d4is a suitable substituent and is selected independently of one another from among —OR^e4, —NR^e4R^e4and halogen;
  - each R^e4independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different R^f4and/or R^g4, selected from among C_1-6alkyl, C_1-6haloalkyl, C_3-10cycloalkyl, C_6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl;
  - each R^f4is a suitable substituent and is selected independently of one another from among —OR^g4, —NR^g4R^g4and halogen as well as the bivalent substituent ═O, which may only be a substituent in non-aromatic ring systems;
  - each R^g4independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different R^h4, selected from among C_1-6alkyl, C_3-10cycloalkyl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl;
  - each R^h4is selected independently of one another from among C_1-6alkyl and the bivalent substituent ═O, which may only be a substituent in non-aromatic ring systems;
  - or
  - the group —NR^gR^e4denotes a nitrogen-containing, 3-14 membered heterocycloalkyl or 5-12 membered heteroaryl, optionally substituted by one or more identical or different group(s) selected from among R^d4and R^e4;
  - the group —NR^gR^e4denotes a nitrogen-containing, 3-14 membered heterocycloalkyl or 5-12 membered heteroaryl, optionally substituted by one or more identical or different group(s) selected from among R^f4and R^g4;
  - the group —NR^gR^g4denotes a nitrogen-containing 3-14 membered heterocycloalkyl or 5-12 membered heteroaryl, optionally substituted by one or more identical or different group(s) R^h4; and
- R⁸is selected from among hydrogen, C_1-6alkyl, —OC_1-6alkyl, —CN, halogen, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl.

In another aspect (F7) the invention relates to compounds (1) with structural aspect F6, wherein
at least one of the groups R⁵to R⁸is not hydrogen.
In another aspect (F8) the invention relates to compounds (1) with structural aspect F6, wherein
R⁵is selected from among
In another aspect (F9) the invention relates to compounds (1), wherein
R²is selected from among
and R′ denotes the binding site to the linker unit L².
In another aspect (F10) the invention relates to compounds (1), wherein
R²is selected from among
and R′ denotes the binding site to the linker unit L².
In another aspect (F11) the invention relates to compounds (1), wherein
R²is selected from among
and R′ denotes the binding site to the linker unit L².
In another aspect (G1) the invention relates to compounds (1), wherein
L²denotes (R²)—NHC(O)—.
In another aspect (G2) the invention relates to compounds (1), wherein
L²denotes (R²)—C(O)NH—.
All the above-mentioned structural aspects A to G relating to different molecular parts of the compounds (1) according to the invention may be permutated with one another as desired to form combinations ABCDEFG, so as to obtain preferred compounds (1). Each combination ABCDEFG represents and defines individual embodiments or generic partial amounts of compounds according to the invention. Every individual embodiment or partial amount defined by this combination is expressly included and is an object of the invention.
In another aspect the invention relates to compounds—or the pharmacologically acceptable salts thereof—of general formula (1) as medicaments.
In another aspect the invention relates to pharmaceutical preparations, containing as active substance one or more compounds of general formula (1) or the pharmacologically acceptable salts thereof, optionally in combination with conventional excipients and/or carriers.
In another aspect the invention relates to compounds of general formula (1) for use in the treatment and/or prevention of cancer, infections, inflammations and autoimmune diseases.
In another aspect the invention relates to compounds of general formula (1) for use in the treatment and/or prevention of cancer.
In another aspect the invention relates to a pharmaceutical preparation comprising a compound of general formula (1), while the compounds (1) may optionally also be in the form of the tautomers, racemates, enantiomers, diastereomers and mixtures thereof or as the respective pharmacologically acceptable salts of all the above-mentioned forms, and at least one other cytostatic or cytotoxic active substance different from formula (1).

DEFINITIONS

As used herein, the following definitions apply, unless stated otherwise:
The use of the prefix C_x-y, where x and y in each case denote a natural number (x<y), indicates that the chain or cyclic structure or combination of chain and cyclic structure referred to and mentioned in direction connection may consist in total of a maximum of y and a minimum of x carbon atoms.
The information as to the number of members in groups containing one or more hetero-atom(s) (heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl) refers to the total atomic number of all the ring members or chain members or the total of all the ring and chain members.
Alkyl is made up of the sub-groups saturated hydrocarbon chains and unsaturated hydrocarbon chains, while the latter may be further subdivided into hydrocarbon chains with a double bond (alkenyl) and hydrocarbon chains with a triple bond (alkynyl). Alkenyl contains at least one double bond, alkynyl at least one triple bond. If a hydrocarbon chain should have both at least one double bond and at least one triple bond, by definition it belongs to the alkynyl sub-group. All the above-mentioned sub-groups may be further subdivided into straight-chain (unbranched) and branched. If an alkyl is substituted, it may be mono- or polysubstituted independently of one another at all the hydrogen-carrying carbon atoms. Examples of individual sub-groups are listed below:

Straight-Chain (Unbranched) or Branched, Saturated Hydrocarbon Chains:

methyl; ethyl; n-propyl; isopropyl (1-methylethyl); n-butyl; 1-methylpropyl; isobutyl (2-methylpropyl); sec.-butyl (1-methylpropyl); tert.-butyl (1.1-dimethylethyl); n-pentyl; 1-methylbutyl; 1-ethylpropyl; isopentyl (3-methylbutyl); neopentyl (2,2-dimethyl-propyl); n-hexyl; 2,3-dimethylbutyl; 2,2-dimethylbutyl; 3,3-dimethylbutyl; 2-methyl-pentyl; 3-methylpentyl; n-heptyl; 2-methylhexyl; 3-methylhexyl; 2,2-dimethylpentyl; 2,3-dimethylpentyl; 2,4-dimethylpentyl; 3,3-dimethylpentyl; 2,2,3-trimethylbutyl; 3-ethylpentyl; n-octyl; n-nonyl; n-decyl etc.

Straight-Chained (Unbranched) or Branched Alkenyl:

vinyl (ethenyl); prop-1-enyl; allyl (prop-2-enyl); isopropenyl; but-1-enyl; but-2-enyl; but-3-enyl; 2-methyl-prop-2-enyl; 2-methyl-prop-1-enyl; 1-methyl-prop-2-enyl; 1-methyl-prop-1-enyl; 1-methylidenepropyl; pent-1-enyl; pent-2-enyl; pent-3-enyl; pent-4-enyl; 3-methyl-but-3-enyl; 3-methyl-but-2-enyl; 3-methyl-but-1-enyl; hex-1-enyl; hex-2-enyl; hex-3-enyl; hex-4-enyl; hex-5-enyl; 2,3-dimethyl-but-3-enyl; 2,3-dimethyl-but-2-enyl; 2-methylidene-3-methylbutyl; 2,3-dimethyl-but-1-enyl; hexa-1,3-dienyl; hexa-1,4-dienyl; penta-1,4-dienyl; penta-1,3-dienyl; buta-1,3-dienyl; 2,3-dimethylbuta-1,3-diene etc.

Straight-Chain (Unbranched) or Branched Alkynyl:

ethynyl; prop-1-ynyl; prop-2-ynyl; but-1-ynyl; but-2-ynyl; but-3-ynyl; 1-methyl-prop-2-ynyl etc.

By the terms propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl etc. unless otherwise stated are meant saturated hydrocarbon groups with the corresponding number of carbon atoms, including all the isomeric forms.
By the terms propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl etc. unless otherwise stated are meant unsaturated hydrocarbon groups with the corresponding number of carbon atoms and a double bond, including all the isomeric forms, also (Z)/(E)-isomers, where applicable.
By the terms butadienyl, pentadienyl, hexadienyl, heptadienyl, octadienyl, nonadienyl, decadienyl etc. unless otherwise stated are meant unsaturated hydrocarbon groups with the corresponding number of carbon atoms and two double bonds, including all the isomeric forms, also (Z)/(E)-isomers, where applicable.
By the terms propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl etc. unless otherwise stated are meant unsaturated hydrocarbon groups with the corresponding number of carbon atoms and a triple bond, including all the isomeric forms.
From alkyl as hereinbefore defined and its subgroups the term alkylene can also be derived. Alkylene unlike alkyl is bivalent and requires two bonding partners. Formally the second valency is produced by removing a hydrogen atom from an alkyl. Corresponding groups are for example —CH₃and —CH₂, —CH₂CH₃and —CH₂CH₂or >CHCH₃etc. For all the subgroups of alkyl there are correspondences for alkylene.
By heteroatoms are meant oxygen, nitrogen and sulphur atoms.
By the term heteroalkyl are meant groups which are derived from the alkyl as hereinbefore defined in its widest sense by replacing, in the hydrocarbon chains, one or more of the groups —CH₃independently of one another by the groups —OH, —SH or —NH₂, one or more of the groups —CH₂— independently of one another by the groups —O—, —S— or —NH—, one or more of the groups >CH— by the group >N—, one or more of the groups ═CH— by the group ═N—, one or more of the groups ═CH₂by the group ═NH or one or more of the groups ≡CH by the group ≡N, while a total of not more than three heteroatoms may be present in one heteroalkyl, there must be at least one carbon atom between two oxygen atoms and between two sulphur atoms or between one oxygen and one sulphur atom and the group as a whole must have chemical stability.
A direct result of the indirect definition/derivation from alkyl is that heteroalkyl is made up of the sub-groups saturated hydrocarbon chains with heteroatom(s), heteroalkenyl and heteroalkynyl, and it may be further subdivided into straight-chain (unbranched) and branched. If a heteroalkyl is substituted, it may be mono- or polysubstituted independently of one another at all the hydrogen-carrying oxygen, sulphur, nitrogen and/or carbon atoms. Heteroalkyl itself as a substituent may be attached to the molecule both through a carbon atom and through a heteroatom. The following are listed by way of example:

dimethylaminomethyl; dimethylaminoethyl (1-dimethylaminoethyl; 2-dimethyl-amino-ethyl); dimethylaminopropyl (1-dimethylaminopropyl, 2-dimethylaminopropyl, 3-dimethylaminopropyl); diethylaminomethyl; diethylaminoethyl (1-diethylamino ethyl, 2-diethylamino ethyl); diethylaminopropyl (1-diethylaminopropyl, 2-diethylamino-propyl, 3-diethylaminopropyl); diisopropylaminoethyl (1-diisopropylaminoethyl, 2-diisopropyl-aminoethyl); bis-2-methoxyethylamino; [2-(dimethylamino-ethyl)-ethyl-amino]-methyl; 3-[2-(dimethylamino-ethyl)-ethyl-amino]-propyl; hydroxymethyl; 2-hydroxy-ethyl; 3-hydroxypropyl; methoxy; ethoxy; propoxy; methoxymethyl; 2-methoxyethyl etc.

From heteroalkyl as hereinbefore defined and its subgroups the term heteroalkylene can also be derived. Heteroalkylene unlike heteroalkyl is bivalent and requires two bonding partners. Formally the second valency is produced by removing a hydrogen atom from a heteroalkyl. Corresponding groups are for example —CH₂NH₂and —CH₂NH— or >CHNH₂, —NHCH₃and >NCH₃or —NHCH₂—, —CH₂OCH₃and —CH₂OCH₂— or >CHOCH₃etc. For all the subgroups of heteroalkyl there are correspondences for heteroalkylene.
Haloalkyl is derived from alkyl as hereinbefore defined in its broadest sense, by replacing one or more hydrogen atoms of the hydrocarbon chain independently of one another by halogen atoms, which may be identical or different. A direct result of the indirect definition/derivation from alkyl is that haloalkyl is made up of the sub-groups saturated hydrohalogen chains, haloalkenyl and haloalkynyl, and it may be further subdivided into straight-chain (unbranched) and branched. If a haloalkyl is substituted, it may be mono- or polysubstituted independently of one another at all the hydrogen-carrying carbon atoms. Typical examples are listed below:
—CF₃; —CHF₂; —CH₂F; —CF₂CF₃; —CHFCF₃; —CH₂CF₃; —CF₂CH₃; —CHFCH₃; —CF₂CF₂CF₃; —CF₂CH₂CH₃; —CF═CF₂; —CCl═CH₂; —CBr═CH₂; —CI═CH₂; —C≡C—CF₃; —CHFCH₂CH₃; —CHFCH₂CF₃etc.
From haloalkyl as hereinbefore defined and its subgroups the term haloalkylene can also be derived. Haloalkylene unlike haloalkyl is bivalent and requires two bonding partners.
Formally the second valency is produced by removing a hydrogen atom from a haloalkyl. Corresponding groups are for example —CH₂F and —CHF—, —CHFCH₂F and —CHFCHF— or >CFCH₂F etc. For all the subgroups of haloalkyl there are correspondences for haloalkylene.
Halogen encompasses fluorine, chlorine, bromine and/or iodine atoms.
Cycloalkyl is made up of the sub-groups monocyclic hydrocarbon rings, bicyclic hydrocarbon rings and spirohydrocarbon rings, while each sub-group may be further subdivided into saturated and unsaturated (cycloalkenyl). By unsaturated is meant that there is at least one double bond in the ring system, but no aromatic system is formed. In bicyclic hydrocarbon rings two rings are linked such that they share at least two carbon atoms. In spirohydrocarbon rings one carbon atom (spiroatom) is shared by two rings. If a cycloalkyl is substituted, it may be mono- or polysubstituted independently of one another at all the hydrogen-carrying carbon atoms. Cycloalkyl itself as a substituent may be attached to the molecule through any suitable position of the ring system. The following individual sub-groups are listed by way of example:

Monocyclic Hydrocarbon Rings, Saturated:

cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; cycloheptyl etc.
Monocyclic hydrocarbon rings, unsaturated:
cycloprop-1-enyl; cycloprop-2-enyl; cyclobut-1-enyl; cyclobut-2-enyl; cyclopent-1-enyl; cyclopent-2-enyl; cyclopent-3-enyl; cyclohex-1-enyl; cyclohex-2-enyl; cyclohex-3-enyl; cyclohept-1-enyl; cyclohept-2-enyl; cyclohept-3-enyl; cyclohept-4-enyl; cyclobuta-1,3-dienyl; cyclopenta-1,4-dienyl; cyclopenta-1,3-dienyl; cyclopenta-2,4-dienyl; cyclohexa-1,3-dienyl; cyclohexa-1,5-dienyl; cyclohexa-2,4-dienyl; cyclohexa-1,4-dienyl; cyclohexa-2,5-dienyl etc.

Bicyclic Hydrocarbon Rings (Saturated and Unsaturated):

bicyclo[2.2.0]hexyl; bicyclo[3.2.0]heptyl; bicyclo[3.2.1]octyl; bicyclo[2.2.2]octyl; bicyclo[4.3.0]nonyl (octahydroindenyl); bicyclo[4.4.0]decyl (decahydronaphthalene); bicyclo[2.2.1]heptyl (norbornyl); (bicyclo[2.2.1]hepta-2,5-dienyl (norborna-2,5-dienyl); bicyclo[2.2.1]hept-2-enyl (norbornenyl); bicyclo[4.1.0]heptyl (norcaranyl); bicyclo-[3.1.1]heptyl (pinanyl) etc.
Spirohydrocarbon Rings (Saturated and Unsaturated):
spiro[2.5]octyl, spiro[3.3]heptyl, spiro[4.5]dec-2-ene, etc.

If the free valency of a cycloalkyl is saturated off, an alicyclic ring is obtained.
From cycloalkyl as hereinbefore defined and its subgroups the term cycloalkylene can also be derived. Cycloalkylene unlike cycloalkyl is bivalent and requires two bonding partners. Formally the second valency is produced by removing a hydrogen atom from a cycloalkyl. Corresponding groups are for example cyclohexyl and
cyclopentenyl and
etc.
For all the subgroups of cycloalkyl there are correspondences for cycloalkylene.
Cycloalkylalkyl refers to the combination of the alkyl in question, as hereinbefore defined, with cycloalkyl, both in their widest sense. Alternatively cycloalkylalkyl may also be regarded as a combination of cycloalkyl with alkylene. Formally, cycloalkylalkyl is obtained by first linking an alkyl as substituent directly with the molecule and then substituting with a cycloalkyl. The linking of alkyl and cycloalkyl may be carried out in both groups using carbon atoms that are suitable for this purpose. The respective subgroups of alkyl (alkylene) and cycloalkyl are also included in the combination of the two groups.
Aryl denotes mono-, bi- or tricyclic carbon rings with at least one aromatic ring. If an aryl is substituted, the substitution may be mono- or polysubstitution in each case, at all the hydrogen-carrying carbon atoms, independently of one another. Aryl itself may be linked to the molecule as substituent via any suitable position of the ring system. Typical examples are listed below:
phenyl, naphthyl, indanyl (2,3-dihydroindenyl), 1,2,3,4-tetrahydronaphthyl; fluorenyl, etc.
If the free valency of an aryl is saturated off, an aromatic group is obtained.
From aryl as hereinbefore defined the term arylene can also be derived. Arylene unlike aryl is bivalent and requires two bonding partners. Formally the second valency is produced by removing a hydrogen atom from an aryl. Corresponding groups are for example phenyl and
naphthyl and
etc. For all the subgroups of aryl there are correspondences for arylene.
Arylalkyl denotes the combination of the groups alkyl and aryl as hereinbefore defined, in each case in their broadest sense. Alternatively arylalkyl may also be regarded as a combination of aryl with alkylene. Formally, arylalkyl is obtained by first linking an alkyl as substituent directly to the molecule and substituting it with an aryl group. The alkyl and aryl may be linked in both groups via any carbon atoms suitable for this purpose. The respective sub-groups of alkyl (alkylene) and aryl are also included in the combination of the two groups. Typical examples are listed below:
benzyl; 1-phenylethyl; 2-phenylethyl; phenylvinyl; phenylallyl etc.
Heteroaryl denotes monocyclic aromatic rings or polycyclic rings with at least one aromatic ring, which, compared with corresponding aryl or cycloalkyl, contain instead of one or more carbon atoms one or more identical or different heteroatoms, selected independently of one another from among nitrogen, sulphur and oxygen, while the resulting group must be chemically stable. The prerequisite for the presence of heteroaryl is a heteroatom and an aromatic system, although it need not necessarily be a heteroaromatic system. Thus 2,3-dihydro-1H-indol-6-yl
may according to the definition be a heteroaryl.
If a heteroaryl is substituted, the substitution may be mono- or polysubstitution in each case, at all the hydrogen-carrying carbon and/or nitrogen atoms, independently of one another. Heteroaryl itself as substituent may be linked to the molecule via any suitable position of the ring system, both carbon and nitrogen. Typical examples are listed below.

Monocyclic Heteroaryls:

furyl; thienyl; pyrrolyl; oxazolyl; thiazolyl; isoxazolyl; isothiazolyl; pyrazolyl; imidazolyl; triazolyl; tetrazolyl; oxadiazolyl; thiadiazolyl; pyridyl; pyrimidyl; pyridazinyl; pyrazinyl; triazinyl; pyridyl-N-oxide; pyrrolyl-N-oxide; pyrimidinyl-N-oxide; pyridazinyl-N-oxide; pyrazinyl-N-oxide; imidazolyl-N-oxide; isoxazolyl-N-oxide; oxazolyl-N-oxide; thiazolyl-N-oxide; oxadiazolyl-N-oxide; thiadiazolyl-N-oxide; triazolyl-N-oxide; tetrazolyl-N-oxide etc.

Polycyclic Heteroaryls

indolyl; isoindolyl; benzofuryl; benzothienyl; benzoxazolyl; benzothiazolyl; benzisoxazolyl; dihydroindolyl; benzisothiazolyl; benzimidazolyl; indazolyl; isoquinolinyl; quinolinyl; quinoxalinyl; cinnolinyl; phthalazinyl; quinazolinyl; benzotriazinyl; indolizinyl; oxazolopyridyl; imidazopyridyl; naphthyridinyl; indolinyl; isochromanyl; chromanyl; tetrahydroisoquinolinyl; isoindolinyl; isobenzotetrahydrofuryl; isobenzotetrahydrothienyl; isobenzothienyl; benzoxazolyl; pyridopyridyl; benzotetrahydrofuryl; benzotetrahydro-thienyl; purinyl; benzodioxolyl; phenoxazinyl; phenothiazinyl; pteridinyl; benzothiazolyl; imidazopyridyl; imidazothiazolyl; dihydrobenzisoxazinyl; benzisoxazinyl; benzoxazinyl; dihydrobenzisothiazinyl; benzopyranyl; benzothiopyranyl; coumarinyl; isocoumarinyl; chromonyl; chromanonyl; tetrahydroquinolinyl; dihydroquinolinyl; dihydroquinolinonyl; dihydroisoquinolinonyl; dihydrocoumarinyl; dihydroisocoumarinyl; isoindolinonyl; benzodioxanyl; benzoxazolinonyl; quinolinyl-N-oxide; indolyl-N-oxide; indolinyl-N-oxide; isoquinolyl-N-oxide; quinazolinyl-N-oxide; quinoxalinyl-N-oxide; phthalazinyl-N-oxide; indolizinyl-N-oxide; indazolyl-N-oxide; benzothiazolyl-N-oxide; benzimidazolyl-N-oxide; benzothiopyranyl-5-oxide and benzothiopyranyl-S,S-dioxide etc.

If the free valency of a heteroaryl is saturated off, a heteroaromatic group is obtained.
From heteroaryl as hereinbefore defined the term heteroarylene can also be derived. Heteroarylene unlike heteroaryl is bivalent and requires two bonding partners. Formally the second valency is produced by removing a hydrogen atom from a heteroaryl.
Corresponding groups are for example pyrrolyl and
2,3-dihydro-1H-indolyl and
etc.
For all the subgroups of heteroaryl there are correspondences for heteroarylene.
Heteroarylalkyl denotes the combination of the alkyl in question as hereinbefore defined with heteroaryl, both in their broadest sense. Alternatively heteroarylalkyl may also be regarded as a combination of heteroaryl with alkylene. Formally heteroarylalkyl is obtained by first linking an alkyl as substituent directly with the molecule and then substituting it with a heteroaryl. The linking of the alkyl and heteroaryl may be achieved on the alkyl side via any carbon atoms suitable for this purpose and on the heteroaryl side via any carbon or nitrogen atoms suitable for this purpose. The respective sub-groups of alkyl (alkylene) and heteroaryl are also included in the combination of the two groups.
By the term heterocycloalkyl are meant groups which are derived from the cycloalkyl as hereinbefore defined if in the hydrocarbon rings one or more of the groups —CH₂— are replaced independently of one another by the groups —O—, —S— or —NH— or one or more of the groups ═CH— are replaced by the group ═N—, while not more than five heteroatoms may be present in total, there must be at least one carbon atom between two oxygen atoms and between two sulphur atoms or between one oxygen and one sulphur atom and the group as a whole must be chemically stable. Heteroatoms may simultaneously be present in all the possible oxidation stages (sulphur→sulphoxide —SO—, sulphone —SO₂—; nitrogen→N-oxide). It is immediately apparent from the indirect definition/derivation from cycloalkyl that heterocycloalkyl is made up of the sub-groups monocyclic hetero-rings, bicyclic hetero-rings and spirohetero-rings, while each sub-group can also be further subdivided into saturated and unsaturated (heterocycloalkenyl). The term unsaturated means that in the ring system in question there is at least one double bond, but no aromatic system is formed. In bicyclic hetero-rings two rings are linked such that they have at least two atoms in common. In spirohetero-rings one carbon atom (spiroatom) is shared by two rings. If a heterocycloalkyl is substituted, the substitution may be mono- or polysubstitution in each case, at all the hydrogen-carrying carbon and/or nitrogen atoms, independently of one another. Heterocycloalkyl itself as substituent may be linked to the molecule via any suitable position of the ring system. Typical examples of individual sub-groups are listed below.

Monocyclic Heterorings (Saturated and Unsaturated):

tetrahydrofuryl; pyrrolidinyl; pyrrolinyl; imidazolidinyl; thiazolidinyl; imidazolinyl; pyrazolidinyl; pyrazolinyl; piperidinyl; piperazinyl; oxiranyl; aziridinyl; azetidinyl; 1,4-dioxanyl; azepanyl; diazepanyl; morpholinyl; thiomorpholinyl; homomorpholinyl; homopiperidinyl; homopiperazinyl; homothiomorpholinyl; thiomorpholinyl-5-oxide; thiomorpholinyl-S,S-dioxide; 1,3-dioxolanyl; tetrahydropyranyl; tetrahydrothiopyranyl; [1,4]-oxazepanyl; tetrahydrothienyl; homothiomorpholinyl-S,S-dioxide; oxazolidinonyl; dihydropyrazolyl; dihydropyrrolyl; dihydropyrazinyl; dihydropyridyl; dihydropyrimidinyl; dihydrofuryl; dihydropyranyl; tetrahydrothienyl-5-oxide; tetrahydrothienyl-S,S-dioxide; homothiomorpholinyl-5-oxide; 2,3-dihydroazet; 2H-pyrrolyl; 4H-pyranyl; 1,4-dihydropyridinyl etc.

Bicyclic Heterorings (Saturated and Unsaturated):

8-azabicyclo[3.2.1]octyl; 8-azabicyclo[5.1.0]octyl; 2-oxa-5-azabicyclo[2.2.1]heptyl; 8-oxa-3-aza-bicyclo[3.2.1]octyl; 3,8-diaza-bicyclo[3.2.1]octyl; 2,5-diaza-bicyclo-[2.2.1]heptyl; 1-aza-bicyclo[2.2.2]octyl; 3,8-diaza-bicyclo[3.2.1]octyl; 3,9-diaza-bicyclo[4.2.1]nonyl; 2,6-diaza-bicyclo[3.2.2]nonyl etc.

Spiro-Heterorings (Saturated and Unsaturated):

1,4-dioxa-spiro[4.5]decyl; 1-oxa-3.8-diaza-spiro[4.5]decyl; and 2,6-diaza-spiro[3.3]heptyl; 2,7-diaza-spiro[4.4]nonyl; 2,6-diaza-spiro[3.4]octyl; 3,9-diaza-spiro[5.5]undecyl; 2,8-diaza-spiro[4.5]decyl etc.

If the free valency of a heterocycloalkyl is saturated off, then a heterocyclic ring is obtained.
From heterocycloalkyl as hereinbefore defined the term heterocycloalkylene can also be derived. Heterocycloalkylene unlike heterocycloalkyl is bivalent and requires two bonding partners. Formally the second valency is produced by removing a hydrogen atom from a heterocycloalkyl. Corresponding groups are for example piperidinyl and
2,3-dihydro-1H-pyrrolyl and
etc. For all the subgroups of heterocycloalkyl there are correspondences for heterocycloalkylene.
Heterocycloalkylalkyl denotes the combination of the alkyl in question as hereinbefore defined with heterocycloalkyl, both in their broadest sense. Alternatively heterocycloalkylalkyl may also be regarded as a combination of heterocycloalkyl with alkylene. Formally heterocycloalkyl is obtained by first linking an alkyl as substituent directly with the molecule and then substituting it with a heterocycloalkyl. The linking of the alkyl and heterocycloalkyl may be achieved on the alkyl side via any carbon atoms suitable for this purpose and on the heterocycloalkyl side via any carbon or nitrogen atoms suitable for this purpose. The respective sub-groups of alkyl and heterocycloalkyl are also included in the combination of the two groups.
By is substituted is meant that a hydrogen atom that is bound directly to the atom under consideration is replaced by another atom or another group of atoms (substituent). Depending on the starting conditions (number of hydrogen atoms) mono- or polysubstitution may take place at an atom.
Bivalent substituents such as for example ═S, ═NR, ═NOR, ═NNRR, ═NN(R)C(O)NRR, ═N₂or the like may only be substituents at carbon atoms, while the bivalent substituent ═O may also be a substituent of sulphur. Generally speaking, substitution by a bivalent substituent may only take place at ring systems and requires exchange for two geminal hydrogen atoms, i.e. hydrogen atoms that are bound to the same carbon atom saturated before the substitution. Substitution by a bivalent substituent is therefore only possible at the group —CH₂— or sulphur atoms of a ring system.
In addition to this, the term “suitable substituent” denotes a substituent which on the one hand is suitable on account of its valency and on the other hand leads to a system with chemical stability.
The following are some abbreviated notations and their structural correspondences:
If for example in the sequence A-B—C the member B were to correspond to the structural detail —N═, this is to be understood as both A=N—C and
A-N═C
If for example in the sequence
the member A were to correspond to the structural detail >C═
this is to be understood as being
In a diagram such as for example
the dotted line indicates that the ring system may be attached to the molecule via the carbon 1 or 2, i.e. is equivalent to the following diagram
For bivalent groups where the valency with which they bind which adjacent group is critical, the corresponding binding partners are given in brackets, wherever it is necessary for clarification, as in the following formulae:

or (R²)—C(O)NH— or (R²)—NHC(O)—;

Groups or substituents are frequently selected from among alternative groups/substituents with a corresponding group designation (e.g. R^a, R^betc). If a group of this kind is used repeatedly to define a compound according to the invention in different parts of the molecule, it should always be borne in mind that the respective uses are to be regarded as being totally independent of one another.

List of Abbreviations


Ac	acetyl
ATP	adenosine triphosphate
Bn	benzyl
Boc	tert.-butyloxycarbonyl
Bu	butyl
c	concentration
chex	cyclohexane
d	day(s)
TLC	thin layer chromatography
DCM	dichloromethane
DEA	diethylamine
DIPEA	N-ethyl-N,N-diisopropylamine (HÜNIG base)
DMAP	4-N,N-dimethylaminopyridine
DME	1,2-dimethoxyethane
DMF	N,N-dimethylformamide
DMSO	dimethylsulphoxide
DPPA	diphenylphosphorylazide
EDTA	ethylenediaminetetraacetic acid
EE	ethyl acetate
EGTA	ethyleneglycoltetraacetic acid
eq	equivalent(s)
ESI	electron spray ionization
Et	ethyl
Et₂O	diethyl ether
EtOH	ethanol
h	hour
HATU	O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyl-
	uronium hexafluorophosphate
hex	hexyl
HPLC	high performance liquid chromatography
Hünig base	N-ethyl-N,N-diisopropylamine
i	iso
cat.	catalyst, catalytically
conc.	concentrated
LC	liquid chromatography
sln.	solution
mCPBA	meta-chloroperbenzoic acid
Me	methyl
MeOH	methanol
min	minutes
MPLC	medium pressure liquid chromatography
MS	mass spectrometry
NMP	N-methylpyrrolidone
NP	normal phase
n.a.	not available
PBS	phosphate-buffered saline
Ph	phenyl
PMSF	benzylsulphonic acid fluoride
Pr	propyl
Py	pyridine
rac	racemic
red.	reduction
R_f(Rf)	retention factor
RP	reversed phase
RT	room temperature
S_N	nucleophilic substitution
TBAF	tetrabutylammonium fluoride
TBME	tert-butylmethylether
TBTU	O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyl-uronium
	tetrafluoroborate
TEA	triethylamine
temp.	temperature
tert.	tertiary
Tf	triflate
TFA	trifluoroacetic acid
THF	tetrahydrofuran
TMS	trimethylsilyl
t_Ret.	retention time (HPLC)
TRIS	tris(hydroxymethyl)-aminomethane
TsOH	para-toluenesulphonic acid
UV	ultraviolet

Features and advantages of the present invention will become apparent from the following detailed Examples, which illustrate the fundamentals of the invention by way of example, without restricting its scope:

Preparation of the Compounds According to the Invention

General

Unless stated otherwise, all the reactions are carried out in commercially obtainable apparatus using methods that are commonly used in chemical laboratories. Starting materials that are sensitive to air and/or moisture are stored under protective gas and corresponding reactions and manipulations therewith are carried out under protective gas (nitrogen or argon).
Microwave reactions are carried out in an initiator/reactor made by Biotage or in an Explorer made by CEM in sealed containers (preferably 2, 5 or 20 mL), preferably with stirring.

Chromatography

For preparative medium pressure chromatography (MPLC, normal phase) silica gel made by Millipore (name: Granula Silica Si-60A 35-70 μm) or C-18 RP-silica gel (RP-phase) made by Macherey Nagel (name: Polygoprep 100-50 C18) is used. Automated normal phase chromatography is also carried out on a CombiFlash Companion XL apparatus in combination with a CombiFlash Foxy 200 fraction collector made by Isco.
For this, commercially obtainable RediSepRf (120 g silica gel) one-way columns are used. The thin layer chromatography is carried out on ready-made silica gel 60 TLC plates on glass (with fluorescence indicator F-254) made by Merck.
The preparative high pressure chromatography (HPLC) of the example compounds according to the invention is carried out with columns made by Waters (names: XTerra Prep. MS C18, 5 μm, 30×100 mm or XTerra Prep. MS C18, 5 μm, 50×100 mm OBD or Symmetrie C18, 5 μm, 19×100 mm or Sunfire C18 OBD, 19×100 mm, 5 μm or Sunfire Prep C 10 μm OBD 50×150 mm or X-Bridge Prep C18 5 μm OBD 19×50 mm), Agilent (name: Zorbax SB-C8 5μm PrepHT 21.2×50 mm) and Phenomenex (names: Gemini C18 5 μm AXIA 21.2×50 mm or Gemini C18 10 μm 50×150 mm). Different gradients of H₂O/acetonitrile or H₂O/MeOH are used to elute the compounds, while 0.1% HCOOH is added to the water.
The preparative high pressure chromatography (HPLC) on normal phase of the example compounds according to the invention is carried out with columns made by Macherey & Nagel (name: Nucleosil, 50-7, 40×250 mm) and VDSoptilab (name: Kromasil 100 NH₂, 10 μM, 50×250 mm). Different gradients of DCM/MeOH are used to elute the compounds, while 0.1% NH₃is added to the MeOH.
The analytical HPLC (reaction control) of intermediate compounds is carried out using columns made by Agilent (names: Zorbax SB-C8, 5 μm, 21.2×50 mm or Zorbax SB-C8 3.5 μm 2.1×50 mm) and Phenomenex (name: Gemini C18 3 μm 2×30 mm). The analytical equipment is also equipped with a mass detector in each case.
HPLC-Mass Spectroscopy/UV-Spectrometry
The retention times/MS-ESI⁺ for characterising the example compounds according to the invention are produced using different HPLC-MS apparatus (high performance liquid chromatography with mass detector). Compounds that elute at the injection peak are given the retention time t_Ret=0.00.
Details of the methods:

HPLC-MS Method 1

HPLC: Agilent 1100 Series
MS: Agilent LC/MSD SL
Column: Waters, Xterra MS C18, 2.5 μm, 2.1×30 mm, Part. No. 186000592
Eluant: A: H₂O with 0.1% HCOOH; B: acetonitrile (HPLC grade)
Detection: MS: Positive and negative mode
Mass range: 120-900 m/z
Flow 1.10 mL/min
Column temp.: 40° C.
Gradient: 0.00 min: 5% eluant B
0.00-2.50 min: 5%→95% eluant B
2.50-2.80 min: 95% eluant B
2.81-3.10 min: 95%→5% eluant B
HPLC-MS method 2
HPLC: HP 1100
MS: Waters ZQ2000
Column: Waters, Sunfire C18, 3.5 μm, 4.6×50 mm
Eluant: A: H₂O with 0.1% TFA; B: acetonitrile with 0.1% TFA (in each case HPLC grade)
Detection: MS: positive mode
Mass range: 120-820 m/z
Flow 1.5 mL/min
Column temp.: 40° C.
Gradient: 0.00 min: 5% eluant B
- 0.00-2.00 min: 5%→100% eluant B
- 2.00-2.50 min: 100% eluant B
- 2.50-2.60 min: 100%→5% eluant B

HPLC-MS-Method 3

HPLC: HP 1100
MS: Waters ZQ2000
Column: Supelco, Ascentis C18, 2.7 μm, 4.6×50 mm
Eluant: A: H₂O with 0.1% TFA; B: acetonitrile with 0.1% TFA (in each case HPLC grade)
Detection: MS: Positive mode
Mass range: 120-820 m/z
Flow 1.5 mL/min
Column temp.: 40° C.
Gradient: 0.00 min: 5% eluant B
0.00-2.00 min: 5%→100% eluant B
2.00-2.50 min: 100% eluant B
2.50-2.60 min: 100%→5% eluant B

The compounds according to the invention are prepared by the methods of synthesis described hereinafter, in which the substituents of the general formulae have the meanings given hereinbefore. These methods are intended as an illustration of the invention, without restricting its subject matter and the scope of the compounds claimed to these examples. Where the preparation of starting compounds is not described, they are commercially obtainable or may be prepared analogously to known compounds or methods described herein. Substances described in the literature are prepared according to the published methods of synthesis.

Example Compounds of Type I:

Trisubstituted pyrimidopyrimidines I may be obtained for example by two alternative methods according to Reaction scheme A (synthesis route 1 or 2).
Starting from 2,4,8-trichloro-pyrimido[5,4-d]pyrimidine P-1a the chlorine atoms are successively substituted. In the first step the substitution is carried out using ammonia in the 4-position. In the second step the 8-position of the intermediate products P-2a is substituted by the aniline components A-1 or A-2, preferably under basically catalysed conditions at elevated temperature.
If A-1 is used the complete left-hand molecular part of the end compounds I is thereby introduced into the intermediate compound Z-2, so that finally there only remains the substitution in the 2-position by components R¹—H (E-3), which are preferably primary and secondary (also cyclic) amines and alcohols (in the form of the alkoxides). The components A-1 are obtained by amide coupling of the nitrocarboxylic acids E-1 with amines E-2 to form the intermediate product Z-1 and subsequent reduction of the nitro group. To carry out the amide coupling common coupling reagents as used in peptide chemistry (e.g. HATU or TBTU), are optionally used or the nitro acids E-1 are activated in some other way, e.g. as acid halides (e.g. with thionyl chloride, oxalyl chloride, GHOSEZ reagent).
By contrast, by using A-2 first of all only the central phenyl or heteroaryl ring and a protected linker fragment (carboxylate) of the later linker L²(e.g. amide) is incorporated, before the group R¹is introduced analogously. Therefore in this case additional reaction steps (saponification, activation, amidation) are needed to obtain compounds I. The amide coupling is carried out as described hereinbefore for the nitro acids E-1.
Alternatively to P-1a other educts P-1 are possible which allow successive and selective substitution, i.e. have other leaving groups.
Both the group R¹and the group R²of compounds I according to the invention may be modified in other reaction steps (not shown), to obtain other compounds I according to the invention. These reaction steps may be reactions of substitution, alkylation, acylation or addition.

a) Method for Synthesising P-1a:

2,4,8-trihydroxy-pyrimido[5,4-d]pyrimidine (40 g, 222 mmol), potassium chloride (1.68 g, 22.53 mmol) and phosphorus pentachloride (152 g, 730 mmol) are placed in phosphorus oxychloride (240 mL). The reaction mixture is refluxed for 5 h. After cooling the mixture is evaporated down, the residue is triturated several times with petroleum ether and decanted off. The precipitate remaining is mixed with ice water, suction filtered, dissolved in DCM, dried on sodium sulphate and filtered off. The mother liquor is mixed with activated charcoal and heated. The activated charcoal is suction filtered, the filtrate is filtered through silica gel, washed with DCM, evaporated down using the rotary evaporator and 2,4,8-trichloro-pyrimido[5,4-d]pyrimidine P-1a (HPLC-MS: MS (M+H)⁺=234/236/238/240) is obtained. P-1a is used further without any further purification (purity approx. 95%).

b) Method for Synthesising P-2a:

P-1a (95%; 4.0 g, 16.14 mmol) is placed in THF (350 mL) and TEA (2.26 mL, 16.14 mmol). The reaction mixture is cooled to approx. −65° C. with a bath of acetone and dry ice. Then ammonia (0.5 M in dioxane; 41.96 mL, 20.98 mmol) is slowly added dropwise. The reaction mixture is stirred further and slowly heated to RT. After 16 h the reaction mixture is evaporated down, the residue is taken up in 300 mL EE and extracted with 1×200 mL and 2×100 mL water. The organic phase is dried on MgSO₄, filtered and evaporated down using the rotary evaporator. The intermediate product P-2a (HPLC-MS: t_Ret.=0.92 min; MS (M+H)⁺=216/218) is further reacted directly.

c) Method for Synthesising A-1a:

4-methyl-3-nitrobenzoic acid E-1a (2.0 g, 11 mmol) is taken up in DCM (40 mL) and mixed with TEA (5.1 mL, 27.6 mmol) and TBTU (3.9 g, 12.2 mmol). After 10 min 4-methoxy-3-trifluoromethylaniline E-2a (2.11 g, 11 mmol) is added and the mixture is stirred for another 2 h at RT. The precipitate formed is filtered off, washed repeatedly with water, dried and Z-1a (MS (M+H)⁺=355) is obtained.
The aromatic nitro compound Z-1a (3.5 g, 9.9 mmol) is taken up in EtOH (30 mL), mixed with an ammonium chloride solution (264 mg, 4.94 mmol in 20 mL H₂O) and heated to 70° C. At this temperature iron powder (5.52 g, 99 mmol) is added batchwise and the mixture is stirred for a further 4 h at 70° C. After cooling it is filtered through silica gel, washed with DCM/MeOH, the filtrate obtained is dried using the rotary evaporator and A-1a is obtained.

d) Method for Synthesising A-1b:

E-1a (2.0 g, 11.04 mmol) is taken up in DCM (40 mL) and mixed with TEA (5.1 mL, 27.6 mmol) and HATU (6.3 g, 16.6 mmol). After 10 min aniline E-2b (3.41 g, 11.04 mmol) is added and the mixture is stirred for another 2 h at RT. For working up it is diluted with water and the phases are separated. The organic phase is extracted 1× with saturated NH₄Cl solution, 1× with saturated NaHCO₃solution and 1× with saturated NaCl solution, dried on MgSO₄, filtered, evaporated down using the rotary evaporator and Z-1b is obtained.
The aromatic nitro compound Z-1b (3.5 g, 8.04 mmol) is taken up in EtOH (30 mL), combined with an ammonium chloride solution (215 mg, 4.02 mmol in 20 mL H₂O) and heated to 70° C. At this temperature iron powder (4.49 g, 80.4 mmol) is added batchwise and the mixture is stirred for a further 5 h at 70° C. After cooling it is filtered through silica gel, washed with DCM/MeOH (9:1), the filtrate obtained is dried using the rotary evaporator and A-1b is obtained.
Analogously to the method for synthesising A-1a and A-1b further anilines A-1 may be obtained from the corresponding educts E-1 and E-2.

e) Method for Synthesising Z-2a:

P-2a (200 mg, 0.93 mmol), aniline A-1a (300 mg, 0.93 mmol) and TEA (155 μL, 1.53 mmol) are placed in DMF (3 mL). The reaction mixture is stirred overnight at 65° C. The reaction mixture is combined with 20 mL water and stirred for 15 min. The precipitate formed is filtered off, washed with diethyl ether, taken up in toluene, evaporated down and Z-2a is obtained.

f) Method for Synthesising Z-2b:

P-2a (200 mg, 0.93 mmol) and aniline A-1c (291 mg, 0.93 mmol) are taken up in dioxane (3 mL). Hydrogen chloride (1M in Et₂O, 5 μL, 0.102 mmol) is added. The reaction mixture is stirred for 25 min at 65° C. in the microwave reactor. The precipitate formed is filtered off, washed with water, taken up in toluene, evaporated down and Z-2b is obtained.
Analogously to the methods for synthesising Z-2a and Z-2b further intermediate compounds Z-2 are obtained by reacting components A-1 with P-2a.

g) Method for Synthesising Example Compound I-1:

Z-2a (50 mg, 0.1 mmol) and N-methylpiperazine E-3a (40 mg, 0.4 mmol) are taken up in 0.5 mL DMSO and DIPEA (180 μL, 1.4 mmol) is added. The reaction mixture is stirred for 25 min at 120° C. in the microwave reactor. The reaction mixture is filtered and purified by preparative HPLC. The product-containing fractions of I-1 (HPLC-MS: t_Ret.=2.17 min; MS (M+H)⁺=568) are freeze-dried.

h) Method for Synthesising Z-3a:

P-2a (1.439 g, 6.6 mmol) and aniline A-2a (1.0 g, 6.05 mmol) are placed in THF (5 mL). The reaction mixture is stirred overnight at RT. The precipitate formed is filtered off, dried and Z-3a is obtained.
Analogously to the method for synthesising Z-3a further intermediate compounds Z-3 are obtained by reacting components A-2 with P-2a.

i) Method for Synthesising Z-4-a:

Ester Z-3a (1.3 g, 3.77 mmol) is taken up in 25 mL DMSO with DIPEA (2.979 mL, 17.4 mmol) and N-methylpiperazine E-3a (0.443 mL, 4.351 mmol) is added. The reaction mixture is stirred for 20 min at 120° C. in the microwave reactor. The reaction mixture is mixed with water, the precipitate formed is filtered off, taken up in toluene, evaporated down 2× azeotropically and Z-4a is obtained.
Analogously to the method for synthesising Z-4-a further intermediate compounds Z-4 are obtained by reacting intermediate compounds Z-3 with components E-3.

j) Method for Synthesising Example Compound I-2:

Methylester Z-4-a (1.216 g, 2.98 mmol) is placed in MeOH (30 mL) and mixed at RT with an aqueous NaOH solution (5.0 mol/L, 12.146 mL, 60.73 mmol). Then the mixture is stirred overnight at 50° C. For working up the pH is adjusted to neutral by the addition of an HCl solution. The reaction mixture is extracted 2× with water/EE (1:1), the organic phases are dried on MgSO₄, filtered, evaporated down and Z-5a is obtained.
Benzoic acid Z-5a (100 mg, 0.25 mmol) is taken up in DCM (5 mL) and mixed under argon with thionyl chloride (300 μL, 2.38 mmol). The reaction mixture is stirred for 1 h at RT. Then the mixture is evaporated down, dried azeotropically with dry toluene and Z-6a is obtained.
Acid chloride Z-6a (100 mg, 0.24 mmol) is taken up in DCM (3 mL) and mixed with 3-bromo-5-trifluoromethyl-phenylamine E-2c (58 mg, 0.24 mmol) and pyridine (100 μL). The reaction mixture is stirred for 2 h at RT. For working up the mixture is evaporated down, taken up in DMSO, filtered and purified by preparative HPLC. The product-containing fractions of I-2 (HPLC-MS: t_Ret.=2.44 min; MS (M+H)⁺=616/618) are freeze-dried.
Analogously to methods a) to g) (synthesis route 1) or a), b) and h) to j) (synthesis route 2) besides I-1 and I-2 the following compounds I-3 to I-88 according to the invention are also prepared (Table 1).

TABLE 1

Example Compounds I-1 to I-88

		t_Ret.(HPLC)	MS
#	Structure	[min]	(M + H)⁺

I-1		2.17	568

I-2		2.44	616/618

I-3		1.70	552

I-4		1.68	524

I-5		1.67	538

I-6		1.67	526

I-7		1.47	621

I-8		1.51	635

I-9		2.14	517

I-10		2.16	600

I-11		2.22	531

I-12		1.94	599

I-13		1.88	613

I-14		1.98	530

I-15		2.18	651

I-16		2.36	665

I-17		2.23	582

I-18		1.91	516

I-19		2.11	524

I-20		2.23	538

I-21		2.27	607

I-22		2.29	621

I-23		2.31	558

I-24		2.38	572

I-25		2.44	641

I-26		2.41	602/604

I-27		2.51	616/618

I-28		2.44	685/687

I-29		2.75	699/701

I-30		2.28	554

I-31		2.31	568

I-32		2.35	637

I-33		2.45	651

I-34		2.04	542

I-35		1.93	530

I-36		1.89	528

I-37		2.38	558

I-38		2.06	586

I-39		2.23	570

I-40		2.10	613

I-41		1.98	560

I-42		2.16	542

I-43		2.12	556

I-44		2.26	613

I-45		2.15	615

I-46		2.46	544

I-47		2.51	584

I-48		2.30	544

I-49		2.29	586

I-50		2.48	614

I-51		2.42	570

I-52		2.18	599

I-53		2.48	556

I-54		2.28	568

I-55		1.67	538

I-56		1.45	621

I-57		1.76	592

I-58		1.73	578

I-59		1.69	538

I-60		1.46	615

I-61		0.0	635

I-62		1.70	552

I-63		2.47	616

I-64		1.71	566

I-65		1.66	550

I-66		1.66	524

I-67		1.82	615

I-68		1.70	552

I-69		1.78	514

I-70		2.38	639

I-71		2.23	563

I-72		1.98	530

I-73		2.17	539

I-74		2.36	572

I-75		2.15	618

I-76		2.32	625

I-77		2.32	637

I-78		2.43	583

I-79		2.44	595

I-80		2.31	526

I-81		2.39	652

I-82		2.23	520

I-83		2.66	562

I-84		2.47	572

I-85		2.11	556

I-86		2.42	627

I-87		2.56	621

I-88		2.42	639

Example Compounds of Type II:

Example compounds II differ from those of type I by an inverted amide bond between the central (hetero-)aromatic six-membered ring and the group R²(Reaction scheme B). These compounds are obtained analogously to the compounds I in terms of the method used, except that the reactivities are inverted accordingly in the educt components E-4 and E-5 or A-4 (compared with E-1 and E-2 or A-2).
For compounds of type II for example the following two synthesis routes are possible: Starting from P-2a the 8-position is substituted by the aniline components A-3 or A-4. With regard to the use of A-3 reference is made to the remarks relating to Reaction scheme
A (synthesis route 1 via intermediate compound Z-2). The components A-3 are obtained by amide coupling of the nitroanilines E-4 with carboxylic acids E-5 to obtain intermediate product Z-7 and subsequent reduction of the nitro group.
When A-4 is used first of all only the central phenyl or heteroaryl ring and the precursor of a linker fragment (nitro→amino) of the later linker L²is incorporated before the group R¹is introduced analogously. In this case additional reaction steps are necessary (reduction, activation, amidation) in order to obtain compounds II.
Both the group R¹and the group R²of compounds II according to the invention may be modified in other reaction steps (not shown), to obtain further compounds II according to the invention. These reaction steps may be reactions of substitution, alkylation, acylation or addition.

a) Method for Synthesising A-3a:

3-trifluoromethylbenzoic acid E-5a (10.03 g, 51.7 mmol) is taken up in 150 mL toluene. a solution of oxalyl chloride (7.6 mL, 57.58 mmol) in 100 mL toluene is added dropwise. DMF (4 mL) is added and the reaction mixture is stirred for 2 h at 90° C. Then it is evaporated down, the residue is taken up in 100 mL DCM and cooled with an ice bath. 4-Methyl-3-nitroaniline E-4-a (8.91 g, 56.8 mmol) and TEA (8.7 mL, 62.14 mmol) are added, the ice bath is removed and the reaction mixture is stirred overnight at RT. For working up it is filtered, washed with DCM and the filtrate is evaporated down. The residue is mixed with 0.5 M NaOH solution (20 mL), the precipitate formed is filtered off and washed with water. The solid is suspended in 20 mL 0.5 M HCl solution and 10 mL EE, stirred for 15 min at RT and filtered off. The solid is suspended in 30 mL TBME, stirred for 10 min in the ultrasound bath, filtered off, dried and Z-7a (HPLC-MS: t_Ret.=2.30 min; MS (M+H)⁺=325) is obtained.
The aromatic nitro compound Z-7a (4.4 g, 13.57 mmol) is taken up in THF (85 mL) and MeOH (15 mL). Pd/C (200 mg) is carefully added. The reaction vessel is filled with 7 bar H₂, the reaction mixture is stirred overnight at RT, filtered through Celite, washed with THF, the filtrate obtained is dried using the rotary evaporator and A-3a (HPLC-MS: t_Ret.=1.73 min; MS (M+H)⁺=295) is obtained.
Analogously to the method for synthesising A-3a further anilines A-3 were obtained from the corresponding educts E-4 and E-5.

b) Method for Synthesising Z-8a:

P-2a (975 mg, 4.51 mmol) is taken up in DMF (25 mL) and TEA (754 μL, 5.41 mmol) is added. The reaction mixture is combined with aniline A-3a (1.327 g, 4.51 mmol) and stirred overnight at RT. For working up 100 mL ice water are added, the precipitate formed is filtered off and Z-8a is obtained.
Analogously to the method for synthesising Z-8a further intermediate compounds Z-8 are obtained by reacting components A-3 with P-2a.

c) Method for Synthesising Example Compound II-1:

Z-8a (50 mg, 0.11 mmol) is taken up in DMSO (900 μL), mixed with N-methylpiperazine E-3a (32 mg, 0.32 mmol) and stirred for 15 min at 150° C. in the microwave reactor. The reaction mixture is purified by preparative HPLC. The product-containing fractions of II-1 (HPLC-MS: t_Ret.=1.59 min; MS (M+H)⁺=538) are freeze-dried.
Analogously to methods a) to c) (synthesis route 1) or synthesis route 2 described, in addition to II-1 the following compounds II-2 to II-19 according to the invention are also prepared (Table 2).

TABLE 2

Example Compounds II-1 to II-19

		t_Ret.(HPLC)	MS
#	Structure	[min]	(M + H)⁺

II-1	1.59	538

II-2	1.63	552

II-3	1.73	553

II-4	1.66	546

II-5	1.80	546

II-6	1.80	546

II-7	2.29	483

II-8	1.42	621

II-9	1.75	592

II-10	1.69	578

II-11	1.64	538

II-12	1.74	615

II-13	1.68	552

II-14	0.0	635

II-15	1.64	552

II-16	2.40	616

II-17	1.68	566

II-18	1.61	550

II-19	1.62	524

Example Compounds of Type III:

2,8-disubstituted pyrimidopyrimidines III may also be obtained for example by the following methods (Reaction scheme C, synthesis routes 1-3).
Starting from 8-chloro-2-methylsulphanyl-pyrimido[5,4-d]pyrimidine P-3a the 8-position is substituted by the aniline components A-1 or A-2, preferably under basically catalysed conditions at elevated temperature.
If A-1 is used (synthesis route 1) the complete left-hand molecular part of the end compounds III is thereby introduced into the intermediate compound Z-12, so that finally there only remains the substitution in the 2-position by components R¹—H (E-3), which are preferably primary and secondary (also cyclic) amines or alcohols (in the form of the alkoxides). For this, however, first the methylsulphanyl group has to be activated in the 2-position by oxidation to form the corresponding sulphoxide/sulphone for the substitution (for the synthesis of the components A-1 cf. the remarks made under Reaction scheme A). In this reaction, a mixture of the sulphoxide and sulphone is usually obtained, which is further reacted as one.
By contrast, by using A-2 (synthesis routes 2 and 3) first of all only the central phenyl or heteroaryl ring and a protected linker fragment (carboxylate) of the later linker L²(e.g. amide) is incorporated, before the group R¹is introduced. With the intermediate compound Z-14 there are the alternative possibilities of either oxidising/activating the methylsulphanyl group, then substituting it with a component E-3 and lastly, after saponification, introducing the group R²(through the component E-2) (synthesis route 2) or first of all carrying out saponification and oxidation and then carrying out the nucleo-philic substitution by E-3 followed by the amide coupling of E-2 (synthesis route 3).
Alternatively to P-3a other educts P-3 are possible which allow successive and selective substitution, i.e. have other leaving groups.
Both the group R¹and the group R²of compounds III according to the invention may be modified in other reaction steps (not shown), to obtain other compounds III according to the invention. These reaction steps may be reactions of substitution, alkylation, acylation or addition.

a) Method for Synthesising P-3a:

8-hydroxy-2-methylsulphanyl-pyrimido[5,4-d]pyrimidine (16.5 g, 85 mmol) is placed in acetonitrile (125 mL), combined with DMF (400 μL) and heated to 30° C. At this temperature the thionyl chloride (16 mL, 215 mmol) is added dropwise. The reaction mixture is stirred for 4.5 h at 95° C. After cooling it is evaporated down, the residue is taken up in DCM and filtered through silica gel. The filtrate is washed with a saturated NaHCO₃solution, dried on Na₂SO₄, filtered off, the solvent removed and P-3a (HPLC-MS: t_Ret.=1.64 min; MS (M+H)⁺=213/215) is obtained.

b) Method for Synthesising Z-12a:

Aniline A-1a (453 mg, 1.4 mmol) and 8-chloro-2-methylsulphanyl-pyrimido[5,4-d]pyrimidine P-3a (270 mg, 1.27 mmol) are placed in dioxane (3 mL) and DIPEA (352 μL, 1.9 mmol) and refluxed overnight. For working up the reaction mixture is evaporated down, the residue is suspended in MeOH, the precipitate formed is filtered off, dried and Z-12a (HPLC-MS: t_Ret.=1.99 min; MS (M+H)⁺=501) is obtained.

c) Method for Synthesising Z-12b:

Aniline A-1b (3.3 g, 8.14 mmol) and 8-chloro-2-methylsulphanyl-pyrimido[5,4-d]pyrimidine P-3a (1.73 g, 8.14 mmol) are placed in acetic acid (20 mL) and stirred overnight at 50° C. For working up the reaction mixture is evaporated down, the residue is suspended in isopropanol/water (1:1), the precipitate formed is filtered off, dried and Z-12b is obtained.
Analogously to the methods for synthesising Z-12a and Z-12b further intermediate compounds Z-12 are obtained by reacting components A-1 with P-3a.

d) Method for Synthesising Example Compound III-1:

Z-12a (310 mg, 0.62 mmol) is taken up in DCM (5 mL). Then at RT mCPBA (70%, 183 mg, 0.74 mmol) is added and the reaction mixture is stirred for 1 h at RT. The precipitate formed is filtered off, washed with DCM, dried and Z-13a is obtained. Sulphoxide/sulphone Z-13a (90 mg, 0.174 mmol) and N-methylpiperazine E-3a (31 μL, 0.28 mmol) are placed in dioxane (0.5 mL). TEA (51 μL, 0.35 mmol) is added dropwise. The reaction mixture is stirred for 2 h at 60° C. For working up the mixture is evaporated down, the residue is suspended in isopropanol/water and filtered off. The solid is washed with water, dissolved in acetonitrile/water/2 M HCl solution, freeze-dried and III-1 (HPLC-MS: t_Ret.=2.18 min; MS (M+H)⁺=553) is obtained.

e) Method for Synthesising Z-14a:

Methyl 3-amino-4-methylbenzoate A-2a (4.04 g, 24.45 mmol) and 8-chloro-2-methylsulphanyl-pyrimido[5,4-c/]pyrimidine P-3a (80%, 5.0 g, 18.81 mmol) are placed in dioxane (8 mL) and DIPEA (4.525 mL, 24.45 mmol) and refluxed overnight with stirring. For working up the reaction mixture is evaporated down, the residue is suspended in MeOH, the precipitate formed is filtered off, dried and Z-14a (HPLC-MS: t_Ret.=2.01 min; MS (M+H)⁺=342) is obtained.
Analogously to the method for synthesising Z-14a further intermediate compounds Z-14 are obtained by reacting components A-2 with P-3a.

f) Method for Synthesising Z-16a:

Z-14a (5.5 g, 16.1 mmol) is taken up in DCM (40 mL), combined at RT with mCPBA (70%, 3.61 g, 16.1 mmol) and stirred for 1 h. The precipitate formed is filtered off, washed with DCM, dried and Z-15a (HPLC-MS: t_Ret.=1.45 min; MS (M+H(+Na))⁺=358(380)) is obtained.
Sulphoxide/sulphone Z-15a (1.0 g, 2.8 mmol) and morpholine E-3b (704 μL, 7.28 mmol) are placed in dioxane (30 mL). TEA (815 μL, 5.6 mmol) is added dropwise to this suspension and then it is heated to 60° C. for 2 h. For working up the mixture is evaporated down, the residue is suspended with iPrOH/water, filtered, dried and Z-16a (HPLC-MS: t_Ret.=1.94 min; MS (M+H)⁺=381) is obtained.

g) Method for Synthesising Z-16b:

Z-14a (5.5 g, 16.1 mmol) is taken up in DCM (40 mL), combined at RT with mCPBA (70%, 3.61 g, 16.1 mmol) and stirred for 1 h. The precipitate formed is filtered off, washed with DCM, dried and Z-15a (HPLC-MS: t_Ret.=1.45 min; MS (M+H(+Na))⁺=358(380)) is obtained.
Sulphoxide/sulphone Z-15a (3.0 g, 8.4 mmol) and 1-(2-methoxyethyl)-piperazine E-3c (2.5 mL, 16.8 mmol) are placed in dioxane (25 mL). TEA (3 mL, 23 mmol) is added dropwise to this suspension and then the mixture is heated to 60° C. for 2 h. For working up the mixture is evaporated down, the residue is suspended with iPrOH/water, filtered, dried and Z-16b (HPLC-MS: t_Ret.=1.95 min; MS (M+H)⁺=438) is obtained.
Analogously to the methods for synthesising Z-16a and Z-16b other intermediate compounds Z-16 are obtained by oxidising components Z-14 and reacting with amines E-3. Further intermediate compounds Z-16 are obtained by reacting with alcohols E-3 (in the form of their alkoxides), e.g. with sodium methoxide.

h) Method for Synthesising Example Compound III-2:

Z-16a (1.0 g, 2.63 mmol) is placed in THF (15 mL) and combined at RT with an aqueous LiOH solution (1 M, 10.5 mL). Then the mixture is refluxed for 2 h with stirring. For working up the pH is adjusted to 5.5 by the addition of a 1N HCl solution. After evaporation in vacuo the precipitate formed is filtered off, washed with water, dried and Z-17a (HPLC-MS: t_Ret.=1.31 min; MS (M+H)⁺=367) is obtained.
Benzoic acid Z-17a (1.1 g, 3.0 mmol) is suspended in thionyl chloride and stirred for 1 h at 60° C. The reaction mixture is evaporated down and dried azeotropically with dry toluene. The acid chloride Z-18a (400 mg, 1.04 mmol) is then taken up in a little NMP (1.2 mL) and combined with 4-methoxy-3-trifluoromethyl-phenylamine E-2a (188 mg, 1.55 mmol) and DIPEA (300 μL, 1.75 mmol). For working up water is added, the precipitate obtained is filtered off, dried and Example compound III-2 (HPLC-MS: t_Ret.=2.20 min; MS (M+H)⁺=540) is obtained.

i) Method for Synthesising Z-17b:

Z-16b (3.42 g, 7.81 mmol) is placed in THF (25 mL) and combined at RT with an aqueous LiOH solution (1.3 g, 31.4 mmol in 10 mL). Then the mixture is refluxed for 2 h with stirring. For working up the pH is adjusted to 5.5 by the addition of a 1N HCl solution. After evaporation in vacuo the precipitate formed is filtered off, washed with 5 mL water, dried and Z-17b (HPLC-MS: t_Ret.=1.05 min; MS (M+H)⁺=424) is obtained.

j) Method for Synthesising Z-20a:

Z-14a (880 mg, 2.58 mmol) is placed in THF (30 mL) and 1M NaOH solution (3.87 mL, 3.87 mmol) is added. The reaction mixture is stirred for 3 h at 50° C. and then overnight at RT. For working up it is concentrated by rotary evaporation, the residue is acidified slightly with dilute HCl solution, the precipitate formed is suction filtered and washed with water. The intermediate product Z-19a (HPLC-MS: t_Ret.=0.83 min; MS (M+H)⁺=328) is triturated with a little EtOH, suction filtered and dried.
Benzoic acid Z-19a (29.0 g, 88.59 mmol) is placed in glacial acetic acid (800 mL) and sodium periodate (19.139 g, 88.59 mmol) is added. The reaction mixture is heated for 3 h to 80° C. After cooling it is mixed with aqueous Na₂S₂O₅solution (15 mL; 10%) and largely concentrated by rotary evaporation. The residue is mixed with water, the precipitate formed is suction filtered, washed with water, dried in the vacuum dryer at 70° C. and Z-20a (HPLC-MS: t_Ret.=1.81 min; MS (M+H)⁺=360) is obtained.
Analogously to the method for synthesising Z-20a further intermediate compounds Z-20 are obtained by saponification of components Z-14 and oxidation.

k) Method for Synthesising Example Compound III-3:

Sulphoxide/sulphone Z-20a (2.0 g, 5.57 mmol), amine E-3d (1.137 g, 11.13 mmol) and DIPEA (1.94 mL, 11.03 mmol) are taken up in DMF (30 mL) and stirred overnight at RT. The solvent is spun off, the residue is mixed with a little water. The precipitate formed is suction filtered, washed with a little cold water, dried and Z-17a (HPLC-MS: t_Ret.=1.47 min; MS (M+H)⁺=382) is obtained.
Benzoic acid Z-17a (50 mg, 0.13 mmol) is suspended in DCM (5 mL). 1-Chloro-N,N,2-trimethylpropenylamine (41 mg, 0.30 mmol) is added and the reaction mixture is stirred for 3 h at RT. Then it is concentrated by rotary evaporation and the residue is suspended in dioxane/acetonitrile (3 mL, 1:1). Benzylamine E-2c (100 mg, 0.50 mmol) and DIPEA (65 mg, 0.50 mmol) are added and the reaction mixture is stirred overnight at RT. For working up the mixture is concentrated by rotary evaporation, the residue is taken up in DMF and the reaction mixture is purified by RP-LC/MS. The product-containing fractions of III-3 (HPLC-MS: t_Ret.=1.91 min; MS (M+H)⁺=525) are freeze-dried.
Analogously to the methods a) to d) (synthesis route 1) or a), e) to h) (synthesis route 2) as well as a), d), i) and k) (synthesis route 3), besides III-1, III-2 and III-3 the following compounds III-4 to III-608 according to the invention are also prepared (Table 3).

TABLE 3

		t_Ret.(HPLC)
#	Structure	[min]	MS (M + H)⁺

III-1	2.18	553

III-2	2.21	540

III-3	1.91	527

III-4	2.27	562

III-5	1.74	575

III-6	2.56	572

III-7	1.73	587

III-8	1.75	601

III-9	1.73	573

III-10	2.46	558

III-11	1.72	617

III-12	2.26	560

III-13	2.41	544

III-14	1.69	561

III-15	1.73	603

III-16	2.27	518

III-17	2.08	558

III-18	1.65	571

III-19	2.33	568

III-20	1.64	583

III-21	1.77	597

III-22	1.64	569

III-23	2.35	554

III-24	1.63	613

III-25	2.29	556

III-26	2.09	540

III-27	2.34	557

III-28	1.63	599

III-29	2.74	514

III-30	2.07	546

III-31	2.32	559

III-32	2.32	556

III-33	2.33	585

III-34	1.65	557

III-35	2.82	542

III-36	1.64	601

III-37	2.69	544

III-38	2.16	528

III-39	2.27	545

III-40	1.64	587

III-41	2.80	502

III-42	2.29	596

III-43	2.41	609

III-44	2.57	606

III-45	2.41	621

III-46	1.78	635

III-47	2.44	607

III-48	2.72	592

III-49	2.40	651

III-50	2.24	594

III-51	2.38	578

III-52	1.70	595

III-53	2.46	637

III-54	2.30	552

III-55	2.29	545

III-56	1.73	558

III-57	2.61	555

III-58	1.72	570

III-59	2.56	584

III-60	1.70	556

III-61	2.51	541

III-62	1.70	600

III-63	2.26	543

III-64	2.43	527

III-65	2.53	544

III-66	1.69	586

III-67	2.57	511

III-68	2.92	521

III-69	2.59	467

III-70	1.57	536

III-71	1.62	550

III-72	1.53	522

III-73	2.25	507

III-74	1.54	566

III-75	1.99	509

III-76	1.99	493

III-77	1.52	510

III-78	1.53	552

III-79	1.94	524

III-80	1.81	507

III-81	1.80	505

III-82	1.89	489

III-83	1.82	463

III-84	2.37	495

III-85	2.66	505

III-86	1.84	520

III-87	2.08	517

III-88	2.50	491

III-89	2.32	493

III-90	2.43	477

III-91	1.78	494

III-92	1.79	536

III-93	2.36	451

III-94	2.15	437

III-95	2.38	518

III-96	2.46	532

III-97	1.54	546

III-98	1.53	298 (M + 2H)²⁺

III-99	1.63	305 (M + 2H)²⁺

III-100	1.55	282 (M + 2H)²⁺

III-101	1.48	285 (M + 2H)²⁺

III-102	1.67	314 (M + 2H)²⁺

III-103	1.62	305 (M + 2H)²⁺

III-104	1.47	304 (M + 2H)²⁺

III-105	1.65	307 (M + 2H)²⁺

III-106	1.68	296 (M + 2H)²⁺

III-107	1.31	307 (M + 2H)²⁺

III-108	1.52	297 (M + 2H)²⁺

III-109	1.59	289 (M + 2H)²⁺

III-110	1.46	291 (M + 2H)²⁺

III-111	1.54	282 (M + 2H)²⁺

III-112	1.64	290 (M + 2H)²⁺

III-113	1.32	307 (M + 2H)²⁺

III-114	1.31

III-115	1.54	276 (M + 2H)²⁺

III-116	1.44	269 (M + 2H)²⁺

III-117	1.67	290 (M + 2H)²⁺

III-118	1.70	314 (M + 2H)²⁺

III-119	1.51	306 (M + 2H)²⁺

III-120	1.72	311 (M + 2H)²⁺

III-121	1.62	313 (M + 2H)²⁺

III-122	1.50	290 (M + 2H)²⁺

III-123	1.45	293 (M + 2H)²⁺

III-124	1.67	322 (M + 2H)²⁺

III-125	1.60	313 (M + 2H)²⁺

III-126	1.44	312 (M + 2H)²⁺

III-127	1.64	315 (M + 2H)²⁺

III-128	1.67	304 (M + 2H)²⁺

III-129	1.28	316 (M + 2H)²⁺

III-130	1.95	610

III-131	1.59	297 (M + 2H)²⁺

III-132	1.43	299 (M + 2H)²⁺

III-133	1.51	290 (M + 2H)²⁺

III-134	1.63	298 (M + 2H)²⁺

III-135	1.29	316 (M + 2H)²⁺

III-136	1.27	316 (M + 2H)²⁺

III-137	1.50	284 (M + 2H)²⁺

III-138	1.41	277 (M + 2H)²⁺

III-139	1.65	298 (M + 2H)²⁺

III-140	1.67	322 (M + 2H)²⁺

III-141	1.53	300 (M + 2H)²⁺

III-142	1.62

III-143	1.53

III-144	1.47	287 (M + 2H)²⁺

III-145	1.61	307 (M + 2H)²⁺

III-146	1.47	306 (M + 2H)²⁺

III-147	1.64	309 (M + 2H)²⁺

III-148	1.31	309 (M + 2H)²⁺

III-149	1.50	299 (M + 2H)²⁺

III-150	1.59	291 (M + 2H)²⁺

III-151	1.46	293 (M + 2H)²⁺

III-152	1.53

III-153	1.63	292 (M + 2H)²⁺

III-154	1.32	309 (M + 2H)²⁺

III-155	1.52	278 (M + 2H)²⁺

III-156	1.44

III-157	1.67	292 (M + 2H)²⁺

III-158	1.76	311 (M + 2H)²⁺

III-159	1.65	313 (M + 2H)²⁺

III-160	1.55	290 (M + 2H)²⁺

III-161	1.41	321 (M + 2H)²⁺

III-162	1.51	293 (M + 2H)²⁺

III-163	1.70	322 (M + 2H)²⁺

III-164	1.64	313 (M + 2H)²⁺

III-165	1.50	312 (M + 2H)²⁺

III-166	1.67	315 (M + 2H)²⁺

III-167	1.72	304 (M + 2H)²⁺

III-168	1.34	316 (M + 2H)²⁺

III-169	1.49	299 (M + 2H)²⁺

III-170	1.56	290 (M + 2H)²⁺

III-171	1.66	298 (M + 2H)²⁺

III-172	1.36	316 (M + 2H)²⁺

III-173	1.34	316 (M + 2H)²⁺

III-174	1.55	284 (M + 2H)²⁺

III-175	1.47	277 (M + 2H)²⁺

III-176	1.69	298 (M + 2H)²⁺

III-177	1.72	322 (M + 2H)²⁺

III-178	1.61	352 (M + 2H)²⁺

III-179	1.28	477

III-180	1.54	536

III-181	1.57	648

III-182	1.57	551

III-183	1.47	475

III-184	1.46	469

III-185	1.28	433

III-186	1.31	318 (M + 2H)²⁺

III-187	1.26	463

III-188	1.57	537

III-189	1.46	461

III-190	1.46	455

III-191	1.27	419

III-192	1.48	311 (M + 2H)²⁺

III-193	1.48	450

III-194	1.51	406

III-195	1.50	564

III-196	1.33	637

III-197	1.28	465

III-198	1.55	524

III-199	1.58	636

III-200	1.57	539

III-201	1.48	463

III-202	1.47	457

III-203	1.29	421

III-204	1.52	312 (M + 2H)²⁺

III-205	1.54	452

III-206	1.88	511

III-207	1.89	526

III-208	1.79	450

III-209	1.79	444

III-210	1.57	408

III-211	1.61	310 (M + 2H)²⁺

III-212	1.67	448

III-213	2.00	507

III-214	2.00	522

III-215	1.92	446

III-216	1.64	555

III-217	1.61	537

III-218	1.65	539

III-219	1.64	567

III-220	1.69	571

III-221	1.57	551

III-222	1.64	553

III-223	1.26	256 (M + 2H)²⁺

III-224	1.66	525

III-225	1.69	555

III-226	1.65	525

III-227	1.57	537

III-228	1.25	249 (M + 2H)²⁺

III-229	1.67	511

III-230	1.69	541

III-231	1.65	543

III-232	1.62	525

III-233	1.66	527

III-234	1.65	555

III-235	1.71	559

III-236	1.58	539

III-237	1.65	541

III-238	1.27	500

III-239	1.68	513

III-240	1.70	543

III-241	2.00	514

III-242	1.90	526

III-243	1.47	244 (M + 2H)²⁺

III-244	2.04	500

III-245	2.12	510

III-246	2.01	522

III-247	1.58	242 (M + 2H)²⁺

III-248	2.16	496

III-249	2.26	526

III-250	1.93	508

III-251	1.49	576

III-252	1.32	325 (M + 2H)²⁺

III-253	1.92	440

III-254	1.71	404

III-255	1.55	303 (M + 2H)²⁺

III-256	1.58	434

III-257	2.04	508

III-258	1.94	432

III-259	1.95	426

III-260	1.72	390

III-261	1.81	524

III-262	2.40	538

III-263	1.12	484

III-264	2.13	502

III-265	2.17	512

III-266	2.14	494

III-267	2.16	496

III-268	2.22	524

III-269	2.24	528

III-270	2.17	510

III-271	1.68	469

III-272	2.20	482

III-273	2.16	519

III-274	1.95	533

III-275	2.10	495

III-276	2.03	493

III-277	2.08	605

III-278	2.15	496

III-279	1.50	526

III-280	1.79	533

III-281	1.76	550

III-282	1.82	545

III-283	1.75	538

III-284	1.80	562

III-285	1.80	520

III-286	1.87	530

III-287	1.82	512

III-288	1.92	542

III-289	1.95	546

III-290	1.88	528

III-291	2.02	530

III-292	1.85	537

III-293	1.67	551

III-294	1.88	498

III-295	2.10	623

III-296	1.46	531

III-297	1.55	541

III-298	1.53	523

III-299	1.56	553

III-300	1.62	557

III-301	1.56	539

III-302	1.85	512

III-303	1.37	562

III-304	1.87	540

III-305	1.45	522

III-306	1.97	528

III-307	1.72	524

III-308	2.38	510

III-309	1.32	485

III-310	1.82	525

III-311	1.53	548

III-312	1.48	634

III-313	1.97	518

III-314	2.16	528

III-315	1.80	510

III-316	1.87	508

III-317	1.86	534

III-318	1.80	506

III-319	1.86	550

III-320	1.61	549

III-321	1.75	511

III-322	1.69	509

III-323	1.86	621

III-324	1.72	524

III-325	1.60	448

III-326	1.59	442

III-327	2.14	512/513

III-328	2.03	516

III-329	2.06	526

III-330	2.03	508

III-331	2.13	542

III-332	2.06	524

III-333	2.05	533

III-334	1.87	547

III-335	2.00	509

III-336	2.40	539

III-337	1.90	544

III-338	1.97	619

III-339	2.41	509

III-340	1.88	535

III-341	2.31	497

III-342	1.48	517

III-343	1.87	527

III-344	1.63	548

III-345	2.23	513

III-346	1.54	408

III-347	2.11	540

III-348	1.91	502

III-349	2.15	510

III-350	2.24	498

III-351	2.20	622

III-352	2.03	516

III-353	1.86	488

III-354	2.14	488

III-355	2.09	511

III-356	2.26	540

III-357	2.08	489

III-358	2.09	477

III-359	2.16	503

III-360	2.35	517

III-361	2.16	517

III-362	2.42	517

III-363	2.13	503

III-364	2.07	489

III-365	2.23	503

III-366	2.27	495

III-367	2.07	484

III-368	2.37	517

III-369	2.22	503

III-370	2.08	601

III-371	2.24	500

III-372	2.06	516

III-373	2.00	529

III-374	2.43	540/542

III-375	2.21	556/558

III-376	2.19	522

III-377	2.36	506

III-378	2.14	535

III-379	2.17	549

III-380	1.54	440

III-381	2.02	493

III-382	2.20	612

III-383	2.20	513

III-384	1.73	506

III-385	2.04	630

III-386	1.81	513

III-387	1.65	506

III-388	1.86	612

III-389	1.93	630

III-390	1.86	544

III-391	1.73	492

III-392	1.63	492

III-393	2.02	515

III-394	2.27	603

III-395	1.96	550

III-396	2.15	534

III-397	2.18	546

III-398	2.03	520

III-399	1.96	520

III-400	2.15	520

III-401	2.02	534

III-402	1.97	601

III-403	2.14	585

III-404	2.17	597

III-405	2.04	571

III-406	2.06	521

III-407	2.60	652

III-408	2.58	664

III-409	2.49	582

III-410	1.83	526

III-411	2.28	542

III-412	2.24	491

III-413	2.66	650

III-414	2.26	612

III-415	2.80	638

III-416	2.64	608

III-417	2.25	620

III-418	2.20	598

III-419	2.48	650

III-420	2.45	599

III-421	2.00	559

III-422	2.45	585

III-423	2.25	567

III-424	2.29	679

III-425	1.96	545

III-426	2.18	568

III-427	2.20	597

III-428	2.50	518

III-429	2.18	522

III-430	2.28	529

III-431	1.85	565

III-432	2.04	623

III-433	2.13	579

III-434	2.03	595

III-435	2.01	581

III-436	1.91	567

III-437	2.10	581

III-438	2.38	612

III-439	2.37	624

III-440	2.49	594

III-441	2.29	622

III-442	2.33	610

III-443	2.24	567

III-444	2.68	595

III-445	2.38	524

III-446	1.98	515

III-447	2.42	543

III-448	1.93	501

III-449	2.72	566

III-450	2.34	610

III-451	2.54	656

III-452	2.36	628

III-453	2.53	613

III-454	2.26	592

III-455	2.76	652

III-456	2.40	638

III-457	2.30	610

III-458	2.33	624

III-459	2.46	595

III-460	2.69	650

III-461	2.41	636

III-462	2.21	608

III-463	2.25	622

III-464	2.49	542

III-465	2.10	504

III-466	2.54	530

III-467	2.35	512

III-468	2.39	500

III-469	2.40	612

III-470	2.37	624

III-471	2.04	490

III-472	2.24	513

III-473	2.31	542

III-474	2.27	491

III-475	2.70	582

III-476	2.23	544

III-477	2.83	570

III-478	2.48	552

III-479	2.65	540

III-480	2.45	531

III-481	2.38	599

III-482	2.28	572

III-483	2.39	599

III-484	2.27	528

III-485	2.49	570

III-486	2.16	585

III-487	2.03	475

III-488	1.99	600

III-489	1.80	572

III-490	2.09	556

III-491	1.92	516

III-492	2.04	530

III-493	2.05	528

III-494	2.34	544

III-495	1.91	530

III-496	1.85	516

III-497	1.75	514

III-498	2.04	732

III-499	2.21	488

III-500	2.54	484

III-501	2.26	683

III-502	2.16	647

III-503	2.28	626

III-504	2.13	502

III-505	1.87	678

III-506	2.17	626

III-507	2.07	590

III-508	2.04	490

III-509	2.47	736

III-510	2.41	621

III-511	2.35	628

III-512	2.13	508

III-513	1.99	502

III-514	2.36	612

III-515	1.95	488

III-516	2.18	489

III-517	2.16	546

III-518	2.30	598

III-519	2.42	497

III-520	2.32	495

III-521	2.36	509

III-522	2.38	531

III-523	2.09	623

III-524	1.99	622

III-525	1.97	595

III-526	1.80	638

III-527	1.86	608

III-528	2.26	627/629

III-529	1.92	639

III-530	1.86	576

III-531	1.89	592

III-532	1.96	592

III-533	2.11	601/603

III-534	2.08	652

III-535	2.01	597

III-536	1.99	585

III-537	1.89	634

III-538	2.18	633

III-539	2.28	623

III-540	2.13	611

III-541	2.38	625

III-542	2.21	613

III-543	2.11	568

III-544	1.92	568

III-545	2.17	568

III-546	1.91	554

III-547	2.15	526

III-548	2.00	554

III-549	1.86	535

III-550	2.14	568

III-551	2.00	554

III-552	1.84	652

III-553	2.24	650

III-554	2.20	650

III-555	2.12	593

III-556	2.27	621

III-557	1.98	636

III-558	1.93	623

III-559	2.11	651

III-560	2.20	607

III-561	2.02	567

III-562	2.22	654

III-563	1.98	571

III-564	2.07	571

III-565*	1.88	447

III-566*	2.37	473

III-567*	2.31	581

III-568*	2.15	455

III-569*	2.11	485

III-570*	2.25	443

III-571*	2.19	555

III-572*	2.28	538

III-573*	2.59	595

III-574*	2.21	567

III-575*	1.85	433

III-576*	2.11	553

III-577*	2.07	434

III-578*	2.08	456

III-579*	2.24	485

III-580	2.21	503

III-581	2.08	503

III-582	2.10	560

III-583	2.23	505

III-584	2.20	554

III-585	2.12	554

III-586	2.12	611

III-587	2.29	556

III-588**	1.98	516

III-589**	2.01	530

III-590**	1.96	518

III-591**	2.02	503

III-592	1.81	571

III-593	1.83	622

III-594	1.94	560

III-595	1.66	526

III-596	2.01	585

III-597	2.05	595

III-598	1.93	504

III-599	2.17	595

III-600	2.18	569

III-601	2.14	604

III-602	1.86	571

III-603	2.04	542

III-604	2.10	580

III-605	1.66	483

III-606	2.00	568

III-607	2.15	642

III-608	2.23	629

*using NaOMe instead of amines (E-3)
**using phenols instead of anilines A-1

Example Compounds of Type IV:

Example compounds IV differ from those of type III by an inverted amide bond between the central (hetero-)aromatic six-membered ring and the group R²(Reaction scheme D). These compounds are obtained analogously to the compounds III in terms of the method used, except that the reactivities are inverted accordingly in the educt components E-4 and E-5 (for the synthesis of A-3, cf. Reaction scheme B) or A-4 (compared with E-1 and E-2 or A-2, cf. Reaction schemes A and C).
For the compound of type IV for example the following two synthesis routes are possible:
Starting from P-3a the 8-position is substituted by the aniline components A-3 or A-4, preferably under basically catalysed conditions at elevated temperature.
With regard to the use of A-3 (synthesis route 1) reference is made to the remarks relating to Reaction scheme C (synthesis route 1 via intermediate compound Z-12) (final substitution by E-3 after oxidative activation of the methylsulphanyl group; regarding the synthesis of components A-3 cf. the remarks under Reaction scheme B).
When A-4 is used (synthesis routes 2 and 3) first of all only the central phenyl or heteroaryl ring and the precursor of a linker fragment (nitro→amino) of the later linker L²is incorporated. With the intermediate compound Z-24 there are the alternative possibilities of either oxidising/activating the methylsulphanyl group, then substituting it with a component E-3 and lastly, after reduction, introducing the group R²(via the component E-5) (synthesis route 2) or first of all carrying out reduction and amide coupling with E-5 and then after oxidative activation carrying out the nucleophilic substitution by E-3 (synthesis route 3).
Both the group R¹and the group R²of compounds IV according to the invention may be modified in other reaction steps (not shown), to obtain further compounds IV according to the invention. These reaction steps may be reactions of substitution, alkylation, acylation or addition.

a) Method for Synthesising Z-24a:

8-chloro-2-methylsulphanyl-pyrimido[5,4-d]pyrimidine P-3a (3 g, 14.11 mmol) and nitroaniline A-4-a (2.21 g, 14.53 mmol) are placed in dioxane (25 mL) and DIPEA (3.393 mL, 18.34 mmol) and refluxed overnight with stirring. For working up the reaction mixture is evaporated down, the residue is suspended in MeOH, the precipitate formed is filtered off, dried and Z-24a (HPLC-MS: t_Ret.=2.05 min; MS (M+H)⁺=329) is obtained.
Analogously to the method for synthesising Z-24a further intermediate compounds Z-24 are obtained by reacting components A-4 with P-3a.

b) Method for Synthesising Z-26a:

Z-24a (5 g, 14.47 mmol) is taken up in DCM (50 mL), combined at RT with mCPBA (3.24 g, 14.47 mmol) and stirred for 2 h at RT. The reaction mixture is filtered off, the filtrate is diluted with DCM and washed 3× with saturated NaHCO₃solution. The organic phase is dried on Na₂SO₄, filtered off, evaporated down and Z-25a is obtained. Z-25a is further reacted directly without any further purification (content of sulphoxide/sulphone approx. 85%).
Sulphoxide/sulphone Z-25a (85%, 1 g, 2.47 mmol) and N-methylpiperazine E-3a (4.381 mL, 3.95 mmol) are placed in dioxane (6 mL). TEA (718 μL, 4.94 mmol) is added dropwise to this suspension, then it is heated to 60° C. and stirred for 1 h. For working up the mixture is evaporated down, the residue is suspended with iPrOH/water, filtered and dried. The precipitate is purified by chromatography on NP with DCM/MeOH (9:1) and Z-26a (HPLC-MS: t_Ret.=1.96 min; MS (M+H)⁺=381) is obtained.
Analogously to the method for synthesising Z-26a further intermediate compounds Z-26 are obtained by oxidation of components Z-24 and reaction with amines E-3. Further intermediate compounds Z-26 are obtained by reacting with alcohols E-3 (in the form of their alkoxides), e.g. with sodium methoxide.

c) Method for Synthesising Example Compound IV-1:

Nitro compound Z-26a (490 mg, 1.29 mmol) is taken up in EtOH (10 mL), combined with ammonium chloride (34 mg, 0.64 mmol) in water (10 mL) and heated to 60° C. At this temperature iron powder (719 mg, 12.88 mmol) is added batchwise and the mixture is stirred for a further 1.5 h at 60° C. After cooling it is filtered through silica gel, washed with DCM/MeOH, the filtrate obtained is dried using the rotary evaporator and Z-27a (HPLC-MS: t_Ret.=1.64 min; MS (M+H)⁺=351) is obtained.
4-methoxy-3-trifluoromethylbenzoic acid E-5b (62 mg, 0.29 mmol) is taken up in NMP (750 μL) and combined with DIPEA (166 μL, 1.03 mmol) and HATU (147 mg, 0.39 mmol). After 1 h aniline Z-27a (90 mg, 0.26 mmol) is added and the mixture is stirred at RT. The reaction mixture is purified by preparative HPLC and Example compound IV-1 (HPLC-MS: t_Ret.=2.17 min; MS (M+H)⁺=553) is obtained.

d) Method for Synthesising Z-29a:

Nitro compound Z-24a (2.96 g, 9.02 mmol) is taken up in dioxane (100 mL), combined with ammonium chloride (241 mg, 4.51 mmol) in water (100 mL) and heated to 70° C. At this temperature iron powder (5.04 g, 90.2 mmol) is added batchwise and the mixture is stirred for a further 5 h at 70° C. After cooling it is filtered through silica gel, washed with DCM/MeOH, the filtrate obtained is dried using the rotary evaporator and Z-28a (HPLC-MS: t_Ret.=1.70 min; MS (M+H)⁺=299) is obtained.
Benzoic acid E-5c (1 g, 5.29 mmol) is taken up in NMP (10 mL) and combined with DIPEA (3.415 mL, 21.14 mmol) and HATU (3.02 g, 7.93 mmol). After 1 h aniline Z-28a (1.58 g, 5.29 mmol) is added and the mixture is stirred at RT. The reaction mixture is mixed with water. The precipitate formed is filtered off, washed repeatedly with water, then dried and Z-29a (HPLC-MS: t_Ret.=2.16 min; MS (M+H)⁺=470) is obtained.
Analogously to the method for synthesising Z-29a further intermediate compounds Z-29 are obtained by reduction of components Z-24 and reaction with acids E-5.

e) Method for Synthesising Example Compound IV-2:

Z-29a (1.91 g, 4.07 mmol) is suspended in DCM (40 mL), combined at 0° C. with mCPBA (950 mg, 4.23 mmol) and stirred for 2 h at RT. The reaction mixture is diluted with DCM and washed 2× with saturated NaHCO₃solution. The organic phase is dried on Na₂SO₄, filtered off, evaporated down and Z-30a is obtained.
Sulphoxide/sulphone Z-30a (1.39 g, 2.86 mmol) is placed in dioxane (10 mL) and mixed with TEA (1.607 mL, 11.45 mmol). Morpholine E-3b (250 μL, 2.86 mmol) is added dropwise to this suspension, it is heated to 60° C. and stirred for 4 h. For working up the mixture is evaporated down, the residue is dissolved with DMF, purified by preparative HPLC and Example compound IV-2 (HPLC-MS: t_Ret.=2.09 min; MS (M+H)⁺=509) is obtained.
Analogously to methods a) to c) (synthesis route 2) or a), d) and e) (synthesis route 3) as well as synthesis route 1 shown, besides IV-1 and IV-2 the following compounds IV-3 to IV-68 according to the invention are also prepared (Table 4).

TABLE 4

		t_Ret.(HPLC)
#	Structure	[min]	MS (M + H)⁺

IV-1	2.17	533

IV-2	2.09	509

IV-3	2.17	523

IV-4	1.99	501

IV-5	2.22	502

IV-6	2.40	541

IV-7	2.04	522

IV-8	2.24	553

IV-9	2.16	621

IV-10	2.13	515

IV-11	2.58	486

IV-12	2.19	467

IV-13	2.30	566

IV-14	2.30	460

IV-15	2.31	498

IV-16	2.51	543

IV-17	2.15	524

IV-18	2.24	623

IV-19	2.23	517

IV-20	2.25	555

IV-21	2.54	557

IV-22	2.16	538

IV-23	2.28	637

IV-24	2.27	531

IV-25	2.28	569

IV-26	2.29	548

IV-27	2.14	536

IV-28	2.05	536

IV-29	2.16	550

IV-30	1.98	509

IV-31	2.20	537

VI-32	1.99	509

IV-33	2.26	529

IV-34	2.18	511

IV-35	2.19	511

IV-36	1.93	550

IV-37	2.13	523

IV-38	2.03	523

IV-39	2.40	551

IV-40*	1.99	454

IV-41*	2.08	447

IV-42*	2.12	485

IV-43*	2.11	455

IV-44*	1.92	433

IV-45*	2.18	485

IV-46*	2.11	553

IV-47*	2.06	535

IV-48*	2.17	434

IV-49*	2.28	447

IV-50*	2.23	489

IV-51*	2.11	456

IV-52*	1.99	454

IV-53**	0.0	497

IV-54**	1.78	485

IV-55**	1.86	497

IV-56**	1.72	471

IV-57**	1.59	471

IV-58**	1.56	457

IV-59**	1.43	511

IV-60**	1.60	469

IV-61**	1.49	559

IV-62**	1.39	499

IV-63**	1.49	455

IV-64**	1.44	443

IV-65**	1.58	457

IV-66**	1.29	429

IV-67	1.96	621

IV-68	1.87	607

*using NaOMe instead of amines (E-3)
**by coupling a sulphonic acid instead of carboxylic acid E-5 to the intermediate Z-27

Example Compounds of Type V and VI:

Compounds of type V and VI are pyrimidopyrimidines monosubstituted in the 8-position (Reaction scheme E).
Starting from 4,8-dichloro-pyrimido[5,4-d]pyrimidine P-4-a, one chlorine atom is substituted nucleophilically by the aniline components A-1 (synthesis route 1), A-2 (synthesis route 2) or A-3 (synthesis route 3) while the other chlorine atom is reductively removed.
The substitution by A-1 or A-2 to obtain the intermediate compounds Z-31 or Z-32 is carried out in comparable manner to the steps illustrated in Reaction scheme A or C (reactions to obtain intermediate compounds Z-2, Z-3, Z-12 or Z-14). Whereas example compounds V may be obtained directly from Z-31 (reduction), saponification and amide coupling with amines E-2 are also necessary in addition to the reduction for the synthesis starting from Z-32.
By using the anilines A-3, after reduction of the intermediate compound Z-36, example compounds VI with an inverted amide bond are obtained (regarding the synthesis of A-1 or A-3 cf. the remarks made on Reaction scheme A or B)

a) Method for Synthesising P-4-a:

4,8-dihydroxypyrimidopyrimidine (2.0 g, 12 mmol) is taken. Phosphorus oxychloride (7.0 mL, 76 mmol) and potassium chloride (2.6 g, 35 mmol) are added. Finally, phosphorus pentachloride (6.2 g, 30 mmol) is added batchwise. The reaction mixture is stirred for 1.5 d at 130° C. and 1.5 d at RT. The excess POCl₃is distilled off, the residue is mixed with water and extracted several times with DCM. The combined organic phases are mixed with MgSO₄, filtered through silica gel and washed with DCM. The filtrate is slowly evaporated down to about 15 mL. The precipitate formed is suction filtered and P-4-a (HPLC-MS: MS (M+H)⁺=200/202/204) is obtained.

b) Method for Synthesising Z-31a:

4,8-dichloropyrimidopyrimidine P-4-a (100 mg, 0.50 mmol) is placed in THF (2 mL) while cooling with ice. Aniline A-1d (195 mg, 0.50 mmol) and DIPEA (0.1 mL, 0.58 mmol) are added. The reaction mixture is thawed to RT overnight and stirred. For working up it is mixed with a little acetonitrile. The precipitate is filtered off, dried and Z-31a is obtained. Analogously to the method for synthesising Z-31a further intermediate compounds Z-31 are obtained by reacting components A-1 with P-4-a.

c) Method for Synthesising Z-32a:

4,8-dichloropyrimidopyrimidine P-4-a (1.0 g, 4.98 mmol) is placed in THF (20 mL) and cooled in the ice bath. Aniline A-2a (840 mg, 4.98 mmol) is added batchwise. The reaction mixture is combined with DIPEA (940 μL, 5.49 mmol) and thawed to RT overnight and stirred. For working up the mixture is evaporated to dryness, taken up in acetonitrile and treated for 5 min in the ultrasound bath. The precipitate is filtered off, washed with a mixture of water and acetonitrile (1:1), dried and Z-32a (HPLC-MS: t_Ret.=1.83 min; MS (M+H)⁺=330) is obtained.
Analogously to the method for synthesising Z-32a further intermediate compounds Z-32 are obtained by reacting components A-2 with P-4-a.

d) Method for Synthesising Z-33a:

Z-32a (1.25 g, 3.79 mmol) is suspended in MeOH (130 mL), combined with Raney nickel and hydrogenated overnight at 2 bar. The reaction mixture is filtered off from the catalyst, evaporated to dryness and Z-33a (HPLC-MS: t_Ret.=1.58 min; MS (M+H)⁺=296) is obtained, which is reacted further without any further working up (purity approx. 80%). Analogously to the method for synthesising Z-33a further intermediate compounds Z-33 are obtained by reduction of intermediate compounds Z-32.
e) Method for Synthesising Example Compound V-1:
Ester Z-33a (80%, 817 mg, 2.21 mmol) is combined with a methanolic LiOH solution (270 mg, 11.05 mmol LiOH in 35 mL MeOH). The reaction mixture is stirred overnight at 60° C. For working up the mixture is diluted with 15 mL water and extracted 1× with DCM. The aqueous phase is adjusted to an acidic pH with 2N HCl solution and extracted 5× with EE. The combined organic phases are extracted 1× with saturated NaCl solution, dried on MgSO₄, filtered, evaporated down and Z-34a (HPLC-MS: t_Ret.=0.11 min; MS (M+H)⁺=282) is obtained.
Benzoic acid Z-34a (462 mg, 1.64 mmol) is suspended in thionyl chloride (10 mL, 134 mmol). The reaction mixture is refluxed for 1 h and stirred overnight at 60° C. The excess thionyl chloride is spun off and the remainder is dried azeotropically 1× with toluene. The acid chloride Z-35a is used again directly.
3-amino-5-tert-butylisoxazole E-2d (58 mg, 0.40 mmol) is placed in DCM (4 mL), combined with pyridine (200 μL, 2.47 mmol) and cooled in the ice bath. Then a solution of the acid chloride Z-35a (120 mg, 0.40 mmol) in 3 mL DCM is added. The reaction mixture is stirred for 1 h at RT. For working up the mixture is diluted with water, the DCM is spun off, placed in solution with DMF and chromatographed by RP-MPLC (7% to 90% acetonitrile). The product-containing fractions of V-1 (HPLC-MS: t_Ret.=1.94 min; MS (M+H)⁺=404) are mixed with 2N HCl solution and freeze-dried.
Analogously to the methods a) and c) to e) (synthesis route 2) or the synthesis route 1 shown, besides V-1 the following compounds V-2 to V-10 according to the invention are prepared (Table 5).
Compound of type VI is synthesised according to synthesis route 3 shown.

TABLE 5

		t_Ret.(HPLC)
#	Structure	[min]	MS (M + H)⁺

V-1		1.94	404

V-2		1.37	433

V-3		2.17	459

V-4		2.04	425

V-5		2.01	523

V-6		1.78	464

V-7		1.96	426

V-8		1.25	508

V-9		1.04	403

V-10		1.07	417

Example Compounds of Type VII and VIII:

Compounds of type VII and VIII are pyrimidopyrimidines disubstituted in the 4- and 8-position (Reaction scheme F).
Starting from 4,8-dichloro-pyrimido[5,4-d]pyrimidine P-4-a (synthesis route 4→Z-37) or the intermediate compounds Z-31, Z-32 or Z-36 (cf. their synthesis from P-4-a according to Reaction scheme E) the chlorine atoms in the 4-position are substituted by R³—H (ammonia, methylamine or water/hydroxide). The other reaction steps according to Reaction scheme F correspond to those already described.

a) Method for Synthesising VII-1:

Substance Z-31b (34%, 141.0 mg, 0.109 mmol) is mixed with methylamine (2M in THF, 1 mL). The reaction mixture is stirred for 20 min at RT. For working up it is evaporated down, the residue is dissolved with DMSO, purified by preparative HPLC and example compound VII-1 (HPLC-MS: t_Ret.=1.85 min; MS (M+H)⁺=433) is obtained.

b) Method for Synthesising Z-42a:

4,8-dichloropyrimidopyrimidine P-4 (2.0 g, 9.95 mmol) is placed in dioxane (40 mL) and cooled in the ice bath. The aniline A-4-a (1.514 g, 9.95 mmol) is taken up in 20 mL dioxane and added dropwise to the 4,8-dichloropyrimidopyrimidine solution. Then dipotassium hydrogen phosphate trihydrate (3 M, 6.633 mL, 19.89 mmol) is added. The reaction mixture is heated to RT and stirred overnight at 65° C. For working up the mixture is cooled and evaporated down. The residue is dissolved in DCM and washed 3× with water. The organic phase is dried on Na₂SO₄, filtered off, evaporated down and Z-42a (HPLC-MS: t_Ret.=1.81 min; MS (M+H)⁺=317) is obtained.

c) Method for Synthesising Z-43a:

Substance Z-42a (100 mg, 0.32 mmol) is mixed with methylamine (2M in THF, 2 mL). The reaction mixture is stirred for 30 min at RT. The precipitate formed is filtered off, washed with a little THF, dried in vacuo and Z-43a (HPLC-MS: t_Ret.=1.68 min; MS (M+H)⁺=312) is obtained.

d) Method for Synthesising VIII-1:

Nitro compound Z-43a (80 mg, 0.26 mmol) is taken up in EtOH (2 mL), mixed with ammonium chloride (7 mg, 0.13 mmol) in water (2 mL) and heated to 75° C. At this temperature iron powder (72 mg, 1.29 mmol) is added batchwise and the mixture is stirred for a further hour at 75° C. After cooling it is filtered through silica gel, washed with DCM/MeOH (9:1), the filtrate obtained is dried using the rotary evaporator and Z-44a (HPLC-MS: t_Ret.=1.25 min; MS (M+H)⁺=282) is obtained.
Benzoic acid E-5c (40 mg, 0.21 mmol) is taken up in DCM (1 mL) and mixed with DIPEA (109 μL, 0.63 mmol) and HATU (88 mg, 0.23 mmol). After 15 min aniline Z-44a (60 mg, 0.21 mmol) is added and the mixture is stirred at RT. For working up the mixture is evaporated down, the residue is dissolved with DMSO, purified by preparative HPLC and example compound VIII-1 (HPLC-MS: t_Ret.=1.78 min; MS (M+H)⁺=453) is obtained.

TABLE 6

		t_Ret.(HPLC)
#	Structure	[min]	MS (M + H)⁺

VII-1		1.85	433

VIII-1		1.78	453

VIII-2		1.74	425

VIII-3		1.88	439

Further Information on Reaction Schemes A to F and all the Types of Example Compounds (I to VIII):

For synthesising compounds (1) according to the invention the key educts E-1, E-2, E-3, E-4, E-5, A-2 and A-4 are needed, in particular. These starting compounds may be obtained in numerous ways. A significant number of such synthesis components are commercially obtainable or may be prepared by the skilled man using routine methods. In addition, these components and their preparation are known from the prior art or may be carried out routinely analogously to methods known in the prior art or may be expanded into these. These include in particular methods published in the following publications: WO 2004/050642, WO 2005/056535, WO 2005/090333, WO 2005/115991, US 2006/100204, WO 2008/003770, WO 2005/023761, WO 2008/021388, WO 2007/075896, WO 2007/056016, WO 2008/089034, WO 2009/003999 and WO 2009/003998.
For educts A-4 there is also the alternative possibility of obtaining them from the aromatic nitro acids A-6 by CURTIUS degradation:
For incorporated linker units L²which are different from —C(O)NH— and —NHC(O)—, the synthesis components required may be converted routinely. Thus, for example, instead of carboxylic acids, sulphonic acids may be used to synthesise the corresponding sulphonamides. Urea linkers are obtained by reacting isocyanates with amines or the compound of two amines via a carbonylbiselectrophil (e.g. CDI, triphosgene).
The following Examples describe the biological activity of the compounds according to the invention, without restricting the invention to these Examples.
Compounds of general formula (1) are characterised by their many possible applications in the therapeutic field. Particular mention should be made of those applications in which the inhibition of specific signal enzymes, particularly the inhibiting effect on the proliferation of cultivated human tumour cells but also on the proliferation of other cells such as endothelial cells, for example, are involved.

Kinase Test B-RAF (V600E)

In a dilution series 10 μL of test substance solution are placed in a multiwell plate. The dilution series is selected so that generally a range of concentrations of 2 μM to 0.119 nM or 0.017 nM is covered. If necessary the initial concentration of 2 μM is changed to 50 μM, 10 μM or 0.4 μM or 0.2857 μM and further dilution is carried out accordingly. The final concentration of DMSO is 5%. 10 μL of the B-Raf (V600E)-kinase solution are pipetted in (containing 0.5 ng B-Raf (V600E)-kinase in 20 mM Tris-HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol, 1 mg/mL bovine serum albumin, 1 mM dithiothreitol) and the mixture is incubated for 24 h at RT under with shaking. The kinase reaction is started by the addition of 20 μL ATP solution [final concentration: 250 μM ATP, 30 mM Tris-HCl pH 7.5, 0.02% Brij, 0.2 mM sodium orthovanadate, 10 mM magnesium acetate, 0.1 mM EGTA, phosphatase cocktail (Sigma, # P2850, dilution recommended by the manufacturer), 0.1 mM EGTA] and 10 μL MEK1 solution [containing 50 ng biotinylated MEK1 (prepared from purified MEK1 according to standard procedure, e.g. with EZ-Link Sulpho-NHS-LC-Biotin reagent, Pierce, #21335) and carried out for 60 min at RT with constant shaking. The reaction is stopped by the addition of 12 μL of a 100 mM EDTA solution and incubation is continued for a further 5 min. 55 μL of the reaction solution are transferred into a streptavidin-coated plate (e.g. Streptawell HighBond, Roche, #11989685001) and shaken gently for 1 h at RT, in order to bind biotinylated MEK1 to the plate. After elimination of the liquid the plate is washed five times with 200 μL of 1×PBS and 100 μL solution of primary antibody plus europium-labelled secondary antibody [Anti Phospho-MEK (Ser217/221), Cell Signaling, #9121 and Eu-Nl labeled goat-anti-rabbit antibody, Perkin Elmer, # AD0105], the primary antibody is diluted 1:2000 and the secondary antibody is diluted to 0.4-0.5 μg/mL in Delfia Assay Buffer (Perkin Elmer, #1244-111). After 1 h shaking at RT the solution is poured away and washed five times with 200 μL Delfia Wash Buffer (Perkin Elmer, #4010-0010/#1244-114). After the addition of 200 μL Enhancement Solution (Perkin Elmer, #4001-0010/#1244-105) the mixture is shaken for 10 min at RT and then measured in a Wallac Victor using the program “Delfia Time Resolved Fluorescence (Europium)”. IC₅₀values are obtained from these dosage-activity curves using a software program (GraphPadPrizm).
Table 7 gives the IC₅₀values determined for the compounds according to the invention using the above B-RAF-kinase test.

	TABLE 7

	#	IC₅₀[nM]

	I-1	26
	I-2	9
	I-3	9
	I-4	7
	I-5	5
	I-6	68
	I-7	3
	I-8	2
	I-9	3
	I-10	1
	I-11	1
	I-12	2
	I-13	4
	I-14	3
	I-15	1
	I-16	1
	I-17	1
	I-18	3
	I-19	57
	I-20	50
	I-21	22
	I-22	13
	I-23	14
	I-24	9
	I-25	3
	I-26	70
	I-27	83
	I-28	13
	I-29	15
	I-30	35
	I-31	58
	I-32	14
	I-33	12
	I-34	2
	I-35	2
	I-36	4
	I-37	4
	I-38	6
	I-39	5
	I-40	3
	I-41	5
	I-42	9
	I-43	4
	I-52	55
	I-53	21
	I-54	5
	I-55	<1
	I-56	<1
	I-57	<1
	I-58	1
	I-59	1
	I-60	<1
	I-61	<1
	I-62	2
	I-63	1
	I-64	<1
	I-65	<1
	I-66	<1
	I-67	3
	I-68	<1
	I-69	2
	I-70	3
	I-71	7
	I-72	12
	I-73	2
	I-74	3
	I-75	54
	I-76	1
	I-77	2
	I-78	8
	I-79	19
	I-80	2
	I-81	3
	I-82	676
	I-83	2203
	I-84	11
	I-85	7
	I-86	4
	I-87	9
	I-88	10
	II-1	26
	II-2	41
	II-3	50
	II-4	81
	II-5	50
	II-6	96
	II-7	15
	II-8	2
	II-9	24
	II-10	25
	II-11	20
	II-12	7
	II-13	7
	II-14	4
	II-15	40
	II-16	45
	II-17	13
	II-18	9
	II-19	9
	III-1	2
	III-2	<1
	III-3	118
	III-4	2
	III-5	2
	III-6	7
	III-7	1
	III-8	3
	III-9	7
	III-10	6
	III-11	4
	III-12	2
	III-13	9
	III-14	3
	III-15	5
	III-16	2
	III-17	3
	III-18	4
	III-19	1
	III-20	3
	III-21	3
	III-22	6
	III-23	7
	III-24	5
	III-25	2
	III-26	24
	III-27	8
	III-28	3
	III-29	2
	III-30	2
	III-31	<1
	III-32	1
	III-33	1
	III-34	2
	III-35	5
	III-36	3
	III-37	4
	III-38	5
	III-39	2
	III-40	2
	III-41	1
	III-42	64
	III-43	972
	III-44	>2000
	III-45	283
	III-46	451
	III-47	95
	III-48	>1000
	III-49	587
	III-50	5
	III-51	381
	III-52	2231
	III-53	318
	III-54	543
	III-55	>150
	III-56	1989
	III-57	1827
	III-58	88
	III-59	835
	III-60	230
	III-61	2242
	III-62	546
	III-63	13
	III-64	>1000
	III-65	4171
	III-66	1139
	III-67	5
	III-68	8
	III-69	6
	III-70	4
	III-71	3
	III-72	4
	III-73	4
	III-74	1
	III-75	1
	III-76	11
	III-77	2
	III-78	2
	III-79	1
	III-80	6
	III-81	2
	III-82	20
	III-83	8
	III-84	2
	III-85	7
	III-86	<1
	III-87	3
	III-88	5
	III-89	4
	III-90	5
	III-91	1
	III-92	1
	III-93	1
	III-94	6
	III-95	2
	III-96	2
	III-97	4
	III-98	2
	III-99	5
	III-100	4
	III-101	1
	III-102	4
	III-103	2
	III-104	1
	III-105	3
	III-106	2
	III-107	1
	III-108	<1
	III-109	2
	III-110	1
	III-111	<1
	III-112	2
	III-113	2
	III-114	2
	III-115	2
	III-116	<1
	III-117	2
	III-118	2
	III-119	3
	III-120	3
	III-121	2
	III-122	2
	III-123	<1
	III-124	3
	III-125	4
	III-126	<1
	III-127	3
	III-128	3
	III-129	2
	III-130	3
	III-131	2
	III-132	<1
	III-133	<1
	III-134	2
	III-135	4
	III-136	3
	III-137	3
	III-138	<1
	III-139	3
	III-140	5
	III-141	2
	III-142	3
	III-143	2
	III-144	<1
	III-145	2
	III-146	<1
	III-147	1
	III-148	1
	III-149	<1
	III-150	2
	III-151	1
	III-152	<1
	III-153	<1
	III-154	4
	III-155	2
	III-156	<1
	III-157	3
	III-158	7
	III-159	5
	III-160	3
	III-161	6
	III-162	<1
	III-163	9
	III-164	2
	III-165	<1
	III-166	4
	III-167	5
	III-168	<1
	III-169	1
	III-170	<1
	III-171	3
	III-172	2
	III-173	1
	III-174	2
	III-175	<1
	III-176	4
	III-177	4
	III-178	2
	III-179	>7000
	III-180	3
	III-181	17
	III-182	245
	III-183	>15000
	III-184	2880
	III-185	>15000
	III-186	26
	III-187	>2000
	III-188	104
	III-189	>15000
	III-190	1535
	III-191	>15000
	III-192	2
	III-193	>15000
	III-194	>2000
	III-195	59
	III-196	16
	III-197	>15000
	III-198	11
	III-199	23
	III-200	971
	III-201	>10000
	III-202	>2000
	III-203	>10000
	III-204	4
	III-205	>2000
	III-206	2
	III-207	11
	III-208	>2000
	III-209	162
	III-210	>2000
	III-211	4
	III-212	>15000
	III-213	3
	III-214	56
	III-215	>10000
	III-216	3
	III-217	2
	III-218	293
	III-219	8
	III-220	5
	III-221	171
	III-222	<1
	III-223	15
	III-224	<1
	III-225	2
	III-226	101
	III-227	41
	III-228	5
	III-229	1
	III-230	6
	III-231	29
	III-232	4
	III-233	571
	III-234	15
	III-235	2
	III-236	1124
	III-237	2
	III-238	87
	III-239	6
	III-240	4
	III-241	48
	III-242	19
	III-243	<1
	III-244	<1
	III-245	460
	III-246	29
	III-247	1
	III-248	2
	III-249	10
	III-250	40
	III-251	19
	III-252	8
	III-253	269
	III-254	2000
	III-255	23
	III-256	15000
	III-257	61
	III-258	15000
	III-259	505
	III-260	2000
	III-261	<1
	III-262	9
	III-263	15
	III-264	2600
	III-265	4
	III-266	1
	III-267	836
	III-268	120
	III-269	33
	III-270	20
	III-271	10
	III-272	2
	III-273	31
	III-274	3
	III-275	2
	III-276	6
	III-277	23
	III-278	88
	III-279	6
	III-280	10000
	III-281	5
	III-282	1400
	III-283	3
	III-284	3
	III-285	274
	III-286	3
	III-287	1
	III-288	2
	III-289	13
	III-290	1
	III-291	21
	III-292	36
	III-293	7
	III-294	1
	III-295	17
	III-296	198
	III-297	1
	III-298	1
	III-299	5
	III-300	4
	III-301	<1
	III-302	115
	III-303	7
	III-304	<1
	III-305	2
	III-306	4
	III-307	114
	III-308	47
	III-309	4
	III-310	50
	III-311	2
	III-312	27
	III-313	200
	III-314	9
	III-315	<1
	III-316	3
	III-317	14
	III-318	2
	III-319	1
	III-320	2
	III-321	<1
	III-322	1
	III-323	11
	III-324	55
	III-325	1400
	III-326	292
	III-327	56
	III-328	442
	III-329	17
	III-330	6
	III-331	10
	III-332	4
	III-333	56
	III-334	10
	III-335	8
	III-336	140
	III-337	2
	III-338	41
	III-339	1
	III-340	4
	III-341	<1
	III-342	2121
	III-343	2
	III-344	7
	III-345	1
	III-346	7000
	III-347	1
	III-348	<1
	III-349	<1
	III-350	<1
	III-351	<1
	III-353	<1
	III-354	20
	III-355	<1
	III-356	<1
	III-357	<1
	III-358	1
	III-359	2
	III-360	3
	III-361	2
	III-362	3
	III-363	<1
	III-364	<1
	III-365	1
	III-366	6
	III-367	2
	III-368	14
	III-369	2
	III-370	1
	III-372	5
	III-373	8
	III-374	2000
	III-375	2000
	III-376	7
	III-377	4
	III-378	8
	III-379	6
	III-380	1400
	III-381	3
	III-382	<1
	III-383	4
	III-384	2
	III-385	2
	III-386	1
	III-387	2
	III-388	<1
	III-389	<1
	III-390	<1
	III-391	1
	III-392	3
	III-393	1
	III-394	1
	III-395	4
	III-396	3
	III-397	4
	III-398	1
	III-399	2
	III-400	4
	III-401	3
	III-402	2
	III-403	3
	III-404	6
	III-405	5
	III-406	3
	III-407	10
	III-408	25
	III-409	9
	III-410	1
	III-411	3
	III-412	5
	III-413	<1
	III-414	7
	III-415	3
	III-416	1
	III-417	<1
	III-418	2
	III-419	1
	III-420	1
	III-421	12
	III-422	5
	III-423	<1
	III-424	6
	III-425	7
	III-426	<1
	III-427	2
	III-428	<1
	III-429	2
	III-430	7
	III-431	3
	III-432	6
	III-433	7
	III-435	1
	III-436	2
	III-437	2
	III-438	6
	III-439	4
	III-440	272
	III-441	2
	III-442	1
	III-443	1
	III-444	4
	III-445	2
	III-446	6
	III-447	13
	III-448	8
	III-449	3
	III-450	3
	III-454	4
	III-455	8
	III-456	3
	III-457	4
	III-458	1
	III-459	2
	III-460	4
	III-461	2
	III-462	1
	III-463	2
	III-465	2
	III-467	2
	III-468	<1
	III-469	<1
	III-470	2
	III-471	4
	III-472	2
	III-473	1
	III-474	1
	III-476	17
	III-480	4
	III-481	1
	III-482	4
	III-483	1
	III-484	3
	III-485	3
	III-486	4
	III-487	13
	III-488	6
	III-489	1
	III-490	2
	III-491	2
	III-492	2
	III-493	5
	III-494	4
	III-495	2
	III-496	2
	III-497	2
	III-499	3
	III-500	<1
	III-501	25
	III-502	8
	III-503	1
	III-504	2
	III-505	49
	III-506	4
	III-507	1
	III-508	3
	III-509	5
	III-510	<1
	III-511	4
	III-512	2
	III-513	1
	III-514	1
	III-515	<1
	III-516	<1
	III-517	3
	III-518	2
	III-519	<1
	III-520	2
	III-521	2
	III-522	3
	III-523	1
	III-524	3
	III-525	3
	III-526	4
	III-527	<1
	III-528	2
	III-529	3
	III-530	582
	III-531	13
	III-532	2
	III-533	6
	III-534	106
	III-535	4
	III-536	1
	III-537	12
	III-538	10
	III-539	2
	III-540	5
	III-541	15
	III-542	12
	III-543	3
	III-544	1
	III-545	2
	III-546	4
	III-547	<1
	III-548	3
	III-549	8
	III-550	4
	III-551	1
	III-552	17
	III-553	2
	III-554	3
	III-555	18
	III-556	7
	III-557	4
	III-558	23
	III-559	14
	III-560	7
	III-561	9
	III-562	1
	III-563	2
	III-564	1
	III-565	11
	III-567	2
	III-568	1
	III-569	2
	III-570	<1
	III-571	2
	III-572	1
	III-575	3
	III-577	2
	III-580	28
	III-581	33
	III-582	74
	III-583	32
	III-584	18
	III-585	27
	III-586	193
	III-587	65
	III-591	1
	III-592	<1
	III-593	1
	III-594	1
	III-595	1
	III-596	2
	III-597	5
	III-598	<1
	III-599	1
	III-600	3
	III-601	6
	III-602	9
	III-603	1
	III-604	3
	III-605	6
	III-606	3
	III-607	1
	III-608	7
	IV-1	13
	IV-2	<1
	IV-3	12
	IV-4	44
	IV-5	129
	IV-7	1
	IV-10	221
	IV-12	1
	IV-13	3
	IV-15	3
	IV-18	9
	IV-22	2
	IV-23	4
	IV-24	72
	IV-26	2
	IV-27	1
	IV-28	1
	IV-29	1
	IV-30	<1
	IV-31	5
	IV-32	1
	IV-33	2
	IV-34	2
	IV-35	2
	IV-36	4
	IV-37	1
	IV-38	2
	IV-39	4
	IV-40	2
	IV-42	13
	IV-46	3
	IV-50	59
	IV-53	10000
	IV-54	10000
	IV-55	10000
	IV-56	10000
	IV-57	10000
	IV-58	49
	IV-59	2000
	IV-60	2000
	IV-61	10000
	IV-62	2000
	IV-63	595
	IV-64	521
	IV-65	2000
	IV-66	10000
	IV-67	2
	IV-68	3
	V-1	2
	V-8	4
	V-9	5
	V-10	14
	VII-1	1
	VIII-1	<1
	VIII-2	30
	VIII-3	13

Measurement of the Inhibition of the Proliferation of Cultivated Human Melanoma Cells (SK-MEL-28, B-RAF^V600EMutated)

For measuring the proliferation of cultivated human tumour cells, cells of the melanoma cell line SK-MEL-28 [American Type Culture Collection (ATCC)] are cultivated in MEM medium, supplemented with 10% foetal calf serum, 2% sodium bicarbonate, 1 mM sodium pyruvate, 1% non-essential amino acids (e.g. from Cambrex, # BE13-114E) and 2 mM glutamine. SK-MEL28 cells are placed in 96-well flat bottomed dishes in a density of 2500 cells per well in supplemented MEM medium (see above) and incubated overnight in an incubator (at 37° C. and 5% CO₂). The active substances are added to the cells in different concentrations, so that a concentration range of 50 μM to 3.2 nM is covered. If necessary the initial concentration of 50 μM is changed to 10 μM or 2 μM and further dilution is carried out accordingly (to 0.6 nM or 0.12 nM). After an incubation period of a further 72 h 20 μL AlamarBlue reagent (Serotec Ltd., # BUF012B) are added to each well and the cells are incubated for a further 3-6 h. The colour change of the AlamarBlue reagent is determined in a fluorescence spectrophotometer (e.g. Gemini, Molecular Devices). EC₅₀values are calculated using a software program (GraphPadPrizm).

Measurement of the Inhibition of the Proliferation of Cultivated Human Melanoma Cells (A375, B-RAF^V600EMutated)

For measuring the proliferation of cultivated human tumour cells, cells of the melanoma cell line A375 [American Type Culture Collection (ATCC)] are cultivated in DMEM medium, supplemented with 10% foetal calf serum and 2% sodium bicarbonate. Test substances are tested on A375 cells according to the procedure described for SK-MEL28 cells (see above), but seeding them at 5000 cells per well.
Most of the example compounds of types I to VIII (Tables 1 to 6) show good to very good activity in the cellular A375 and SK-MEL-28 proliferation test, i.e. an EC₅₀value of less than 5 μM, generally less than 1 μM.
The active substances are characterised in that they have a significantly lower antiproliferative effect on cell lines that do not have a B-RAF mutation, i.e. the EC₅₀value is generally higher, by a factor of 10, than the EC₅₀value of B-RAF mutated cell lines.
The cellular selectivity of the active substances is demonstrated by the fact that the EC₅₀value of the phospho-ERK reduction correlates with the EC₅₀value of the antiproliferative activity in B-RAF mutated cell lines.

Measurement of the Reduction in the Phospho-Erk Signal in Cultivated Human Melanoma Cells (SK-MEL-28, B-RAF^V600EMutated)

In order to measure the reduction in the phospho-ERK signal of cultivated human tumour cells, cells of the melanoma cell line SK-MEL-28 [American Type Culture Collection (ATCC)] are cultivated in MEM medium, supplemented with 10% foetal calf serum, 2% sodium bicarbonate, 1 mM sodium pyruvate, 1% non-essential amino acids (e.g. from Cambrex, # BE13-114E) and 2 mM glutamine. SK-MEL28 cells are placed in 96-well flat bottomed dishes at a density of 7500 cells per well in supplemented MEM medium (see above) and incubated overnight in an incubator (at 37° C. and 5% CO₂). The active substances are added to the cells in different concentrations, so that a concentration range of 10 μM to 2.4 nM is covered. If necessary the initial concentration of 10 μM is changed to 50 μM or 2.5 μM and further dilution is carried out accordingly (to 12.2 nM or 0.6 nM). After an incubation period of a further 2 h the cells are fixed with 4% formaldehyde and rendered permeable with 0.1% Triton X-100 in PBS. Non-specific antibody binding is reduced by incubation with 5% skimmed milk powder dissolved in TBS-T. Phosphorylated ERK is detected with a mouse monoclonal anti-diphosphorylated ERK1/2 antibody (from Sigma, #M8159). After washing steps with 0.1% Tween 20 in PBS the bound first antibody is detected by the second antibody (peroxidase coupled polyclonal rabbit anti mouse IgG from DAKO #P0161). After further washing steps, the substrate (TMB Peroxidase Substrate Solution from Bender MedSystems #BMS406) is added. The colour reaction is stopped after a few minutes with 1 M phosphoric acid. The colour is measured with a Spectra max Plus reader from Molecular Devices at 450 nm. EC₅₀values are calculated using a software program (GraphPadPrizm).
The substances of the present invention are B-RAF-kinase inhibitors. As can be demonstrated by DNA staining followed by FACS or Cellomics Array Scan analysis, the inhibition of proliferation achieved by means of the compounds according to the invention is brought about above all by preventing entry into the DNA synthesis phase. The treated cells arrest in the G1 phase of the cell cycle.
Accordingly, the compounds according to the invention are also tested on other tumour cells. For example these compounds are effective on the colon carcinoma line, e.g. Colo205, and may be used in this and other indications. This demonstrates the usefulness of the compounds according to the invention for the treatment of different types of tumours.
On the basis of their biological properties the compounds of general formula (1) according to the invention, their tautomers, racemates, enantiomers, diastereomers, mixtures thereof and the salts of all the above-mentioned forms are suitable for treating diseases characterised by excessive or abnormal cell proliferation.
Such diseases include for example: viral infections (e.g. HIV and Kaposi's sarcoma); inflammatory and autoimmune diseases (e.g. colitis, arthritis, Alzheimer's disease, glomerulonephritis and wound healing); bacterial, fungal and/or parasitic infections; leukaemias, lymphomas and solid tumours (e.g. carcinomas and sarcomas), skin diseases (e.g. psoriasis); diseases based on hyperplasia which are characterised by an increase in the number of cells (e.g. fibroblasts, hepatocytes, bones and bone marrow cells, cartilage or smooth muscle cells or epithelial cells (e.g. endometrial hyperplasia)); bone diseases and cardiovascular diseases (e.g. restenosis and hypertrophy). They are also suitable for protecting proliferating cells (e.g. hair, intestinal, blood and progenitor cells) from DNA damage caused by radiation, UV treatment and/or cytostatic treatment.
For example, the following cancers may be treated with compounds according to the invention, without being restricted thereto: brain tumours such as for example acoustic neurinoma, astrocytomas such as pilocytic astrocytomas, fibrillary astrocytoma, protoplasmic astrocytoma, gemistocytary astrocytoma, anaplastic astrocytoma and glioblastoma, brain lymphomas, brain metastases, hypophyseal tumour such as prolactinoma, HGH (human growth hormone) producing tumour and ACTH producing tumour (adrenocorticotropic hormone), craniopharyngiomas, medulloblastomas, meningeomas and oligodendrogliomas; nerve tumours (neoplasms) such as for example tumours of the vegetative nervous system such as neuroblastoma sympathicum, ganglioneuroma, paraganglioma (pheochromocytoma, chromaffinoma) and glomus-caroticum tumour, tumours on the peripheral nervous system such as amputation neuroma, neurofibroma, neurinoma (neurilemmoma, Schwannoma) and malignant Schwannoma, as well as tumours of the central nervous system such as brain and bone marrow tumours; intestinal cancer such as for example carcinoma of the rectum, colon, anus, small intestine and duodenum; eyelid tumours such as basalioma or basal cell carcinoma; pancreatic cancer or carcinoma of the pancreas; bladder cancer or carcinoma of the bladder; lung cancer (bronchial carcinoma) such as for example small-cell bronchial carcinomas (oat cell carcinomas) and non-small cell bronchial carcinomas such as plate epithelial carcinomas, adenocarcinomas and large-cell bronchial carcinomas; breast cancer such as for example mammary carcinoma such as infiltrating ductal carcinoma, colloid carcinoma, lobular invasive carcinoma, tubular carcinoma, adenocystic carcinoma and papillary carcinoma; non-Hodgkin's lymphomas (NHL) such as for example Burkitt's lymphoma, low-malignancy non-Hodgkin's lymphomas (NHL) and mucosis fungoides; uterine cancer or endometrial carcinoma or corpus carcinoma; CUP syndrome (Cancer of Unknown Primary); ovarian cancer or ovarian carcinoma such as mucinous, endometrial or serous cancer; gall bladder cancer; bile duct cancer such as for example Klatskin tumour; testicular cancer such as for example seminomas and non-seminomas; lymphoma (lymphosarcoma) such as for example malignant lymphoma, Hodgkin's disease, non-Hodgkin's lymphomas (NHL) such as chronic lymphatic leukaemia, leukaemic reticuloendotheliosis, immunocytoma, plasmocytoma (multiple myeloma), immunoblastoma, Burkitt's lymphoma, T-zone mycosis fungoides, large-cell anaplastic lymphoblastoma and lymphoblastoma; laryngeal cancer such as for example tumours of the vocal cords, supraglottal, glottal and subglottal laryngeal tumours; bone cancer such as for example osteochondroma, chondroma, chondroblastoma, chondromyxoid fibroma, osteoma, osteoid osteoma, osteoblastoma, eosinophilic granuloma, giant cell tumour, chondrosarcoma, osteosarcoma, Ewing's sarcoma, reticulo-sarcoma, plasmocytoma, fibrous dysplasia, juvenile bone cysts and aneurysmatic bone cysts; head and neck tumours such as for example tumours of the lips, tongue, floor of the mouth, oral cavity, gums, palate, salivary glands, throat, nasal cavity, paranasal sinuses, larynx and middle ear; liver cancer such as for example liver cell carcinoma or hepatocellular carcinoma (HCC); leukaemias, such as for example acute leukaemias such as acute lymphatic/lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML); chronic leukaemias such as chronic lymphatic leukaemia (CLL), chronic myeloid leukaemia (CML); stomach cancer or gastric carcinoma such as for example papillary, tubular and mucinous adenocarcinoma, signet ring cell carcinoma, adenosquamous carcinoma, small-cell carcinoma and undifferentiated carcinoma; melanomas such as for example superficially spreading, nodular, lentigo-maligna and acral-lentiginous melanoma; renal cancer such as for example kidney cell carcinoma or hypernephroma or Grawitz's tumour; oesophageal cancer or carcinoma of the oesophagus; penile cancer; prostate cancer; throat cancer or carcinomas of the pharynx such as for example nasopharynx carcinomas, oropharynx carcinomas and hypopharynx carcinomas; retinoblastoma such as for example vaginal cancer or vaginal carcinoma; plate epithelial carcinomas, adenocarcinomas, in situ carcinomas, malignant melanomas and sarcomas; thyroid carcinomas such as for example papillary, follicular and medullary thyroid carcinoma, as well as anaplastic carcinomas; spinalioma, epidormoid carcinoma and plate epithelial carcinoma of the skin; thymomas, cancer of the urethra and cancer of the vulva.
The new compounds may be used for the prevention, short-term or long-term treatment of the above-mentioned diseases, optionally also in combination with radiotherapy or other “state-of-the-art” compounds, such as e.g. cytostatic or cytotoxic substances, cell proliferation inhibitors, anti-angiogenic substances, steroids or antibodies.
The compounds of general formula (1) may be used on their own or in combination with other active substances according to the invention, optionally also in combination with other pharmacologically active substances.
Chemotherapeutic agents which may be administered in combination with the compounds according to the invention, include, without being restricted thereto, hormones, hormone analogues and antihormones (e.g. tamoxifen, toremifene, raloxifene, fulvestrant, megestrol acetate, flutamide, nilutamide, bicalutamide, aminoglutethimide, cyproterone acetate, finasteride, buserelin acetate, fludrocortisone, fluoxymesterone, medroxyprogesterone, octreotide), aromatase inhibitors (e.g. anastrozole, letrozole, liarozole, vorozole, exemestane, atamestane), LHRH agonists and antagonists (e.g. goserelin acetate, luprolide), inhibitors of growth factors (growth factors such as for example “platelet derived growth factor” and “hepatocyte growth factor”, inhibitors are for example “growth factor” antibodies, “growth factor receptor” antibodies and tyrosinekinase inhibitors, such as for example cetuximab, gefitinib, imatinib, lapatinib and trastuzumab); antimetabolites (e.g. antifolates such as methotrexate, raltitrexed, pyrimidine analogues such as 5-fluorouracil, capecitabin and gemcitabin, purine and adenosine analogues such as mercaptopurine, thioguanine, cladribine and pentostatin, cytarabine, fludarabine); antitumour antibiotics (e.g. anthracyclins such as doxorubicin, daunorubicin, epirubicin and idarubicin, mitomycin-C, bleomycin, dactinomycin, plicamycin, streptozocin); platinum derivatives (e.g. Cisplatin, oxaliplatin, carboplatin); alkylation agents (e.g. Estramustin, meclorethamine, melphalan, chlorambucil, busulphan, dacarbazin, cyclophosphamide, ifosfamide, temozolomide, nitrosoureas such as for example carmustin and lomustin, thiotepa); antimitotic agents (e.g. Vinca alkaloids such as for example vinblastine, vindesin, vinorelbin and vincristine; and taxanes such as paclitaxel, docetaxel); topoisomerase inhibitors (e.g. epipodophyllotoxins such as for example etoposide and etopophos, teniposide, amsacrin, topotecan, irinotecan, mitoxantron) and various chemotherapeutic agents such as amifostin, anagrelid, clodronat, filgrastin, interferon alpha, leucovorin, rituximab, procarbazine, levamisole, mesna, mitotane, pamidronate and porfimer.
Suitable preparations include for example tablets, capsules, suppositories, solutions—particularly solutions for injection (s.c., i.v., i.m.) and infusion—elixirs, emulsions or dispersible powders. The content of the pharmaceutically active compound(s) should be in the range from 0.1 to 90 wt.-%, preferably 0.5 to 50 wt.-% of the composition as a whole, i.e. in amounts which are sufficient to achieve the dosage range specified below. The doses specified may, if necessary, be given several times a day.
Suitable tablets may be obtained, for example, by mixing the active substance(s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate. The tablets may also comprise several layers.
Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar. To achieve delayed release or prevent incompatibilities the core may also consist of a number of layers. Similarly the tablet coating may consist of a number of layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.
Syrups or elixirs containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavour enhancer, e.g. a flavouring such as vanillin or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.
Solutions for injection and infusion are prepared in the usual way, e.g. with the addition of isotonic agents, preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid, optionally using emulsifiers and/or dispersants, whilst if water is used as the diluent, for example, organic solvents may optionally be used as solvating agents or dissolving aids, and transferred into injection vials or ampoules or infusion bottles.
Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gelatine capsules. Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the derivatives thereof.
Excipients which may be used include, for example, water, pharmaceutically acceptable organic solvents such as paraffins (e.g. petroleum fractions), vegetable oils (e.g. groundnut or sesame oil), mono- or polyfunctional alcohols (e.g. ethanol or glycerol), carriers such as e.g. natural mineral powders (e.g. kaolins, clays, talc, chalk), synthetic mineral powders (e.g. highly dispersed silicic acid and silicates), sugars (e.g. cane sugar, lactose and glucose) emulsifiers (e.g. lignin, spent sulphite liquors, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (e.g. magnesium stearate, talc, stearic acid and sodium lauryl sulphate).
The preparations are administered by the usual methods, preferably by oral or transdermal route, most preferably by oral route. For oral administration the tablets may, of course contain, apart from the abovementioned carriers, additives such as sodium citrate, calcium carbonate and dicalcium phosphate together with various additives such as starch, preferably potato starch, gelatine and the like. Moreover, lubricants such as magnesium stearate, sodium lauryl sulphate and talc may be used at the same time for the tabletting process. In the case of aqueous suspensions the active substances may be combined with various flavour enhancers or colourings in addition to the excipients mentioned above.
For parenteral use, solutions of the active substances with suitable liquid carriers may be used.
The dosage for intravenous use is from 1-1000 mg per hour, preferably between 5 and 500 mg per hour.
However, it may sometimes be necessary to depart from the amounts specified, depending on the body weight, the route of administration, the individual response to the drug, the nature of its formulation and the time or interval over which the drug is administered. Thus, in some cases it may be sufficient to use less than the minimum dose given above, whereas in other cases the upper limit may have to be exceeded. When administering large amounts it may be advisable to divide them up into a number of smaller doses spread over the day.
The formulation examples which follow illustrate the present invention without restricting its scope:

Examples of Pharmaceutical Formulations


A)	Tablets	per tablet

	active substance according to formula (1)	100 mg
	lactose	140 mg
	corn starch	240 mg
	polyvinylpyrrolidone	15 mg
	magnesium stearate	5 mg
		500 mg

The finely ground active substance, lactose and some of the corn starch are mixed together. The mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried. The granules, the remaining corn starch and the magnesium stearate are screened and mixed together. The mixture is compressed to produce tablets of suitable shape and size.


B)	Tablets	per tablet

	active substance according to formula (1)	80 mg
	lactose	55 mg
	corn starch	190 mg
	microcrystalline cellulose	35 mg
	polyvinylpyrrolidone	15 mg
	sodium-carboxymethyl starch	23 mg
	magnesium stearate	2 mg
		400 mg

The finely ground active substance, some of the corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is screened and worked with the remaining corn starch and water to form a granulate which is dried and screened. The sodiumcarboxymethyl starch and the magnesium stearate are added and mixed in and the mixture is compressed to form tablets of a suitable size.


	C)	Ampoule solution

active substance according to formula (1)	50	mg
sodium chloride	50	mg
water for inj.	5	mL

The active substance is dissolved in water at its own pH or optionally at pH 5.5 to 6.5 and sodium chloride is added to make it isotonic. The solution obtained is filtered free from pyrogens and the filtrate is transferred under aseptic conditions into ampoules which are then sterilised and sealed by fusion. The ampoules contain 5 mg, 25 mg and 50 mg of active substance.

Claims

1. A compound of formula (1)

wherein

R¹denotes hydrogen or a group optionally substituted by one or more identical or different R^band/or R^c, selected from among C_1-6alkyl, C_1-6haloalkyl, C_3-10cycloalkyl, C_6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl,

or

a suitable substituent, selected from among —OR^c, —SR^c, —NR^cR^c, —NR^gNR^cR^cand —S(O)R^c;

R²denotes a group optionally substituted by one or more identical or different R^band/or R^c, selected from among C_1-6alkyl, C_1-6haloalkyl, C_3-10cycloalkyl, C_6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl;

R³is selected from among hydrogen, C_1-4alkyl, halogen, —OH, —O(C_1-4alkyl), —NH₂, —NH(C_1-4alkyl) and —N(C_1-4alkyl)₂;

R⁴is selected from among hydrogen, —CN, —NO₂, —NH₂, —NH(C_1-4alkyl), —N(C_1-4alkyl)₂, C_1-4alkyl, C_1-4haloalkyl, C_1-4alkoxy, C_1-5cycloalkyl and halogen;

X¹, X²and X³are each selected independently of one another from among nitrogen and CR⁴*,

wherein at most two of the atoms X¹, X²and X³may be nitrogen atoms and R^4*are each selected independently of one another from among hydrogen, —CN, —NO₂, —NH₂, —NH(C_1-4alkyl), —N(C_1-4alkyl)₂, C_1-4alkyl, C_1-4haloalkyl, C_1-4alkoxy, C_1-5cycloalkyl and halogen;

L¹is selected from among —CH₂—, —NH—, —NMe-, —O— and —S—;

L²is selected from among —C(O)NH—, —C(O)N(C_1-4alkyl)-, —NHC(O)—, —N(C_1-4alkyl)C(O)—, —CH₂—NHC(O)—, —C(O)—, —C(S)NH—, —NHC(S)—, —NHCH₂—, —CH₂NH—, —S(O)₂NH—, —NHS(O)₂—, —NHC(O)NH—, —OC(O)NH— and —NHC(O)O—;

each R^bis a suitable substituent and is selected independently of one another from among —OR^c, —SR^c, —NR^cR^c, —ONR^cR^c, —N(OR^c)R^c, —NR^gNR^cR^c, halogen, —CN, —NO₂, —N₃, —C(O)R^c, —C(O)OR^c, —C(O)NR^cR^c, —C(O)NR^gNR^cR^c, —C(O)NR^gOR^c, —C(NR^g)R^c, —N═CR^cR^c, —C(NR^g)OR^c, —C(NR^g)NR^cR^c, —C(NR^g)NR^gNR^cR^c, —C(NOR^g)R^c, —C(NOR^g)NR^cR^c, —C(NNR^gR^g)R^c, —OS(O)R^c, —OS(O)OR^c, —OS(O)NR^cR^c, —OS(O)₂R^c, —OS(O)₂OR^c, —OS(O)₂NR^cR^c, —OC(O)R^c, —OC(O)OR^c, —OC(O)NR^cR^c, —OC(NR^g)R^c, —OC(NR^g)NR^cR^c, —ONR^gC(O)R^c, —S(O)R^c, —S(O)OR^c, —S(O)NR^cR^c, —S(O)₂R^c, —S(O)₂OR^c, —S(O)₂NR^cR^c, —NR^gC(O)R^c, —NR^gC(O)OR^c, —NR^gC(O)NR^cR^c, —NR^gC(O)NR^gNR^cR^c, —NR^gC(NR^g)R^c, —N═CR^cNR^cR^c, —NR^gC(NR^g)OR^c, —NR^gC(NR^g)NR^cR^c, —NR^gC(NOR^g)R^c, —NR^gS(O)R^c, —NR^gS(O)OR^c, —NR^gS(O)₂R^c, —NR^gS(O)₂OR^c, —NR^gS(O)₂NR^cR^c, —NR^gNR^gC(O)R^c, —NR^gNR^gC(O)NR^cR^c, —NR^gNR^gC(NR^g)R^cand —N(OR^g)C(O)R^cand the bivalent substituents ═O, ═S, ═NR^g, ═NOR^g, ═NNR^gR^gand ═NNR^gC(O)NR^gR^g, while these bivalent substituents may only be substituents in non-aromatic ring systems;

each R^cindependently of one another denotes hydrogen or a group optionally substituted by one or more identical or different R^dand/or R^e, selected from among C_1-6alkyl, 2-6 membered heteroalkyl, C_1-6haloalkyl, C_3-10cycloalkyl, C_6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl;

each R^dis a suitable substituent and is selected independently of one another from among —OR^e, —SR^e, —NR^eR^e, —ONR^eR^e, —N(OR^e)R^e, —N(R^g)NR^eR^e, halogen, —CN, —NO, —NO₂, —N₃, —C(O)R^e, —C(O)OR^e, —C(O)NR^eR^e, —C(O)NR^gNR^eR^e, —C(O)NR^gOR^e, —C(NR^g)R^e, —N═CR^eR^e, —C(NR^g)OR^e, —C(NR^g)NR^eR^e, —C(NR^g)NR^gNR^eR^e, —C(NOR^g)R^e, —C(NOR^g)NR^eR^e, —C(NNR^gR^g)R^e, —OS(O)R^e, —OS (O)OR^e, —OS(O)NR^eR^e, —OS(O)₂R^e, —OS(O)₂OR^e, —OS(O)₂NR^eR^e, —OC(O)R^e, —OC(O)OR^e, —OC(O)NR^eR^e, —OC(NR^g)R^e, —OC(NR^g)NR^eR^e, —ONR^gC(O)R^e, —S(O)R^e, —S(O)OR^e, —S(O)NR^eR^e, —S(O)₂R^e, —S(O)₂OR^e, —S(O)₂NR^eR^e, —NR^gC(O)R^e, —NR^gC(O)OR^e, —NR^gC(O)NR^eR^e, —NR^gC(O)NR^gNR^eR^e, —NR^gC(NR^g)R^e, —N═CR^eNR^eR^e, —NR^gC(NR^g)OR^e, —NR^gC(NR^g)NR^eR^e, —NR^gC(NR^g)SR^e, —NR^gC(NOR^g)R^e, —NR^gS(O)R^e, —NR^gS(O)OR^e, —NR^gS(O)₂R^e, —NR^gS(O)₂OR^e, —NR^gS(O)₂NR^eR^e, —NR^gNR^gC(O)R^e, —NR^gNR^gC(O)NR^eR^e, —NR^gNR^gC(NR^g)R^eand —N(OR^g)C(O)R^eand the bivalent substituents ═O, ═S, ═NR^g, ═NOR^g, ═NNR^gR^gand ═NNR^gC(O)NR^gR^g, while these bivalent substituents may only be substituents in non-aromatic ring systems;

each R^eindependently of one another denotes hydrogen or a group optionally substituted by one or more identical or different R^fand/or R^g, selected from among C_1-6alkyl, 2-6 membered heteroalkyl, C_1-6haloalkyl, C_3-10cycloalkyl, C_6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl;

each R^fis a suitable substituent and is selected independently of one another from among the se bivalenten OR^g, —SR^g, —NR^gR^g, —ONR^gR^g, —N(OR^g)R^g, —N(R^h)NR^gR^g, halogen, —CN, —NO₂, —N₃, —C(O)R^g, —C(O)OR^g, —C(O)NR^gR^g, —C(O)NR^hNR^gR^g, —C(O)NR^hOR^g, —C(NR^h)R^g, —N═CR^gR^g, —C(NR^h)OR^g, —C(NR^h)NR^gR^g, —C(NR^h)NR^hNR^gR^g, —C(NOR^h)R^g, —C(NOR^h)NR^gR^g, —C(NNR^hR^h)R^g, —OS(O)R^g, —OS(O)OR^g, —OS(O)NR^gR^g, —OS(O)₂R^g, —OS(O)₂OR^g, —OS(O)₂NR^gR^g, —OC(O)R^g, —OC(O)OR^g, —OC(O)NR^gR^g, —OC(NR^h)R^g, —OC(NR^h)NR^gR^g, —ONR^hC(O)R^g, —S(O)R^g, —S(O)OR^g, —S(O)NR^gR^g, —S(O)₂R^g, —S(O)₂OR^g, —S(O)₂NR^gR^g, —NR^hC(O)R^g, —NR^hC(O)OR^g, —NR^hC(O)NR^gR^g, —NR^hC(O)NR^hNR^gR^g, —NR^hC(NR^h)R^g, —N═CR^gNR^gR^g, —NR^hC(NR^h)OR^g, —NR^hC(NR^h)NR^gR^g, —NR^hC(NOR^h)R^g, —NR^hS(O)R^g, —NR^hS(O)OR^g, —NR^hS(O)₂R^g, —NR^hS(O)₂OR^g, —NR^hS(O)₂NR^gR^g, —NR^hNR^hC(O)R^g, —NR^hNR^hC(O)NR^gR^g, —NR^hNR^hC(NR^h)R⁹and —N(OR^h)C(O)R^gand the bivalent substituents ═O, ═S, ═NR^h, ═NOR^h, ═NNR^hR^hand ═NNR^hC(O)NR^hR^h, while these bivalent substituents may only be substituents in non-aromatic ring systems;

each R^gindependently of one another denotes hydrogen or a group optionally substituted by one or more identical or different R^h, selected from among C_1-6alkyl, 2-6 membered heteroalkyl, C_1-6haloalkyl, C_3-10cycloalkyl, C_6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl;

each R^his selected independently of one another from among hydrogen, C_1-6alkyl, 2-6 membered heteroalkyl, C_1-6haloalkyl, C_3-10cycloalkyl, C_6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl;

tautomer, racemate, enantiomer, diastereomer or a mixture thereof, or pharmacologically acceptable salt thereof.

2. The compound according to claim 1, wherein R¹is a group optionally substituted by one or more identical or different R^band/or R^c, selected from among 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl.

3. The compound according to claim 2, wherein R¹is a 3-7 membered, monocyclic and nitrogen-containing heterocycloalkyl or 6-10 membered, bicyclic and nitrogen-containing heterocycloalkyl optionally substituted by one or more identical or different R^band/or R^c, and

R¹is bound to the pyrimido[5,4-d]pyrimidine structure via a nitrogen atom.

4. The compound according to claim 2, wherein R¹is heterocycloalkyl, which is bound to the pyrimido[5,4-d]pyrimidine structure via a nitrogen atom and is optionally substituted by one or more substituents, each independently selected from among R^b1and R^c1;

each R^b1is selected independently of one another from among —OR^c1, —NR^c1R^c1, halogen, —C(O)R^c1and ═O, wherein the latter substituent may only be a substituent in non-aromatic ring systems,

each R^c1independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different R^d1and/or R^e1, selected from among C_1-6alkyl, phenyl, C_3-10cycloalkyl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl,

each R^d1is selected independently of one another from among —OR^e1and —NR^e1R^e1,

each R^e1independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different C_1-6alkyl, selected from among C_1-6alkyl, C_3-10cycloalkyl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl.

5. The compound according to claim 1, wherein R¹denotes —NR^c2R^c3.

6. The compound according to claim 5, wherein R¹denotes —NR^c2R^c3and

R^c2is selected from among hydrogen, C_1-6alkyl, C_3-6cycloalkyl, phenyl, 5-6 membered heteroaryl and 3-7 membered heterocycloalkyl,

R^c3is a group optionally substituted by one or more identical or different R^d3and/or R^e3, selected from among C_1-6alkyl, C_1-6haloalkyl, C_3-10cycloalkyl and 3-14 membered heterocycloalkyl,

each R^d3is selected independently of one another from among halogen, —NR^e3R^e3and —OR^e3,

each R^f3independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different R^f3and/or R^g3, selected from among C_1-6alkyl, C_6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl,

each R^f3denotes —OR^g3and

each R^g3is selected independently of one another from among hydrogen and C_1-6alkyl.

7. The compound according to claim 1, wherein

X¹denotes CR^4*-1, X²denotes CR^4*-2and X³denotes CR^4*-3and

R^4*-1, R^4*-2and R^4*-3are each selected from among hydrogen, fluorine, bromine, chlorine and methyl and at least two of the groups R^4*-1, R^4*-2and R^4*-3denote hydrogen.

8. The compound according to claim 1, wherein

X¹denotes nitrogen, X²denotes CR^4*-2and X³denotes CR^4*-3and

R^4*-2and R^4*-3are each selected from among hydrogen, fluorine, bromine, chlorine and methyl and at least one of the groups R^4*-2and R^4*-3denotes hydrogen.

9. The compound according to claim 1, wherein

R²is a group optionally substituted by one or more identical or different R^band/or R^c, selected from among C_6-10aryl and 5-12 membered heteroaryl.

10. The compound according to claim 9, wherein R²is a group optionally substituted by one or more identical or different R^band/or R^c, selected from among phenyl and 5-6 membered heteroaryl.

11. The compound according to claim 10, wherein R²is a heteroaryl which is selected from among furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, triazolyl, isoxazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl and pyrimidyl, and is optionally substituted by one or two substituents, each independently selected from among C_3-7cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, 1-methylpropyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, 1-methylbutyl, 1-ethylpropyl, isopentyl, Neopentyl, trifluoromethyl, difluoromethyl, fluoromethyl, tert.-butoxy, trifluoromethoxy,

12. The compound according to claim 10, wherein R²denotes a phenyl

R⁵is selected from among hydrogen, C_1-6alkyl, —OC_1-6alkyl, C_1-6haloalkyl, —OC_1-6haloalkyl, C_3-7cycloalkyl and 3-7 membered heterocycloalkyl, all the above-mentioned groups optionally being substituted by C_1-6alkyl, —CN or —OH;

R⁶is selected from among hydrogen, C_1-6alkyl, —OC_1-6alkyl, C_1-6haloalkyl, —OC_1-6haloalkyl, —CN, —OH, halogen, —NHC_1-6alkyl and —N(C_1-6alkyl)₂, the latter two optionally being substituted in the alkyl moiety by a substituent —N(C_1-6alkyl)₂;

R⁷is selected from among hydrogen, —OC_1-6alkyl, halogen, —NHS(O)₂C_1-6alkyl, —S(O)₂NH₂, —S(O)₂NHC_1-6alkyl, —S(O)₂N(C_1-6alkyl)₂,

R⁹is selected from among hydrogen and C_1-6alkyl;

R^c4denotes hydrogen or a group optionally substituted by one or more identical or different R^d4and/or R^e4, selected from among C_1-6alkyl and 3-14 membered heterocycloalkyl;

each R^d4is a suitable substituent and is selected independently of one another from among —OR^e4, —NR^e4R^e4and halogen;

each R^e4independently of one another denote hydrogen or a group optionally substituted by one or more identical or different R^f4and/or R^g4, selected from among C_1-6alkyl, C_1-6haloalkyl, C_3-10cycloalkyl, C_6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl;

each R^f4is a suitable substituent and is selected independently of one another from among —OR^g4, —NR^g4R^g4and halogen as well as the bivalent substituent ═O, which may only be a substituent in non-aromatic ring systems;

each R^g4independently of one another denote hydrogen or a group optionally substituted by one or more identical or different R^h4, selected from among C_1-6alkyl, C_3-10cycloalkyl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl;

each R^h4is selected independently of one another from among C_1-6alkyl and the bivalent substituent ═O, which may only be a substituent in non-aromatic ring systems;

or

the group —NR⁹R^c4denotes a nitrogen-containing, 3-14 membered heterocycloalkyl or 5-12 membered heteroaryl, optionally substituted by one or more identical or different group(s) selected from among R^d4and R^e4;

the group —NR⁹R^e4denotes a nitrogen-containing, 3-14 membered heterocycloalkyl or 5-12 membered heteroaryl, optionally substituted by one or more identical or different group(s) selected from among R^f4and R^g4;

the group —NR⁹R^g4denotes a nitrogen-containing, 3-14 membered heterocycloalkyl or 5-12 membered heteroaryl, optionally substituted by one or more identical or different group(s) R^h4; and

R⁸is selected from among hydrogen, C_1-6alkyl, —OC_1-6alkyl, —CN, halogen, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl.

13. The compound according to claim 12, wherein R⁵is selected from among

14. (canceled)

15. A pharmaceutical preparation, comprising as active substance one or more compound of formula (1) according to claim 1.

16. (canceled)

17. (canceled)

18. A pharmaceutical preparation comprising a compound of formula (1) according to claim 1, and at least one other cytostatic or cytotoxic active substance different from formula (1).

19. A method for the prevention of or treatment of cancer, infection, inflammation or autoimmune disease in a warm-blooded animal which comprises administering to said animal an effective amount of a compound according to claim 1.

20. The method as recited in claim 19 for the prevention of or treatment of cancer.